WO2021261601A1 - レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 - Google Patents
レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 Download PDFInfo
- Publication number
- WO2021261601A1 WO2021261601A1 PCT/JP2021/024382 JP2021024382W WO2021261601A1 WO 2021261601 A1 WO2021261601 A1 WO 2021261601A1 JP 2021024382 W JP2021024382 W JP 2021024382W WO 2021261601 A1 WO2021261601 A1 WO 2021261601A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- drug
- group
- agent
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 368
- 201000011510 cancer Diseases 0.000 title claims abstract description 266
- 239000003814 drug Substances 0.000 title claims abstract description 136
- 229940079593 drug Drugs 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 66
- 150000004492 retinoid derivatives Chemical class 0.000 title claims abstract description 52
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 23
- 238000002648 combination therapy Methods 0.000 title claims abstract description 7
- 238000011282 treatment Methods 0.000 title abstract description 24
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 61
- 210000004027 cell Anatomy 0.000 claims description 93
- 239000012830 cancer therapeutic Substances 0.000 claims description 79
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims description 79
- 229950010130 tamibarotene Drugs 0.000 claims description 75
- 229940124597 therapeutic agent Drugs 0.000 claims description 72
- 230000000694 effects Effects 0.000 claims description 60
- 230000008595 infiltration Effects 0.000 claims description 47
- 238000001764 infiltration Methods 0.000 claims description 47
- 238000007901 in situ hybridization Methods 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims description 26
- 230000001629 suppression Effects 0.000 claims description 26
- 229940126585 therapeutic drug Drugs 0.000 claims description 24
- 239000003550 marker Substances 0.000 claims description 23
- 239000002246 antineoplastic agent Substances 0.000 claims description 22
- 230000009471 action Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 19
- 230000002708 enhancing effect Effects 0.000 claims description 15
- 239000002955 immunomodulating agent Substances 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 229940127089 cytotoxic agent Drugs 0.000 claims description 12
- 229940088597 hormone Drugs 0.000 claims description 12
- 239000005556 hormone Substances 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 9
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 6
- 238000011532 immunohistochemical staining Methods 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims description 3
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 78
- 201000002528 pancreatic cancer Diseases 0.000 description 78
- 241000699666 Mus <mouse, genus> Species 0.000 description 55
- 210000001519 tissue Anatomy 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 48
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 47
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 47
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 45
- 229960005277 gemcitabine Drugs 0.000 description 45
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 43
- 208000008443 pancreatic carcinoma Diseases 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 35
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 33
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 30
- -1 VTP194204) Chemical compound 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 24
- 101150020966 Acta2 gene Proteins 0.000 description 22
- 108010035532 Collagen Proteins 0.000 description 18
- 102000008186 Collagen Human genes 0.000 description 18
- 229920001436 collagen Polymers 0.000 description 18
- 238000002054 transplantation Methods 0.000 description 18
- 230000004614 tumor growth Effects 0.000 description 18
- 238000001574 biopsy Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 11
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 11
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 11
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 11
- 238000010187 selection method Methods 0.000 description 11
- 108010085238 Actins Proteins 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 230000007704 transition Effects 0.000 description 10
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 9
- 229940041181 antineoplastic drug Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- 210000002705 pancreatic stellate cell Anatomy 0.000 description 8
- 229930002330 retinoic acid Natural products 0.000 description 8
- 230000002269 spontaneous effect Effects 0.000 description 8
- 101000977638 Homo sapiens Immunoglobulin superfamily containing leucine-rich repeat protein Proteins 0.000 description 7
- 102100023538 Immunoglobulin superfamily containing leucine-rich repeat protein Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000711408 Murine respirovirus Species 0.000 description 7
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 101150008656 COL1A1 gene Proteins 0.000 description 6
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 6
- 201000011519 neuroendocrine tumor Diseases 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 101150008975 Col3a1 gene Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 208000004707 mucinous cystadenoma Diseases 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 4
- SZWKGOZKRMMLAJ-UHFFFAOYSA-N 4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(=O)NC1=CC=C(C(O)=O)C=C1 SZWKGOZKRMMLAJ-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 208000006336 acinar cell carcinoma Diseases 0.000 description 4
- 208000030317 anaplastic cancer Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 229960000575 trastuzumab Drugs 0.000 description 4
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- BOOOLEGQBVUTKC-NVQSDHBMSA-N (2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BOOOLEGQBVUTKC-NVQSDHBMSA-N 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 108010069502 Collagen Type III Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HZLFFNCLTRVYJG-WWGOJCOQSA-N Patidegib Chemical compound C([C@@]1(CC(C)=C2C3)O[C@@H]4C[C@H](C)CN[C@H]4[C@H]1C)C[C@H]2[C@H]1[C@H]3[C@@]2(C)CC[C@@H](NS(C)(=O)=O)C[C@H]2CC1 HZLFFNCLTRVYJG-WWGOJCOQSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 108090000064 retinoic acid receptors Proteins 0.000 description 3
- 102000003702 retinoic acid receptors Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LOMMPXLFBTZENJ-ZACQAIPSSA-N F[C@H]1[C@H](C2=C(C=CC(=C2[C@H]1F)OC=1C=C(C#N)C=C(C=1)F)S(=O)(=O)C)O Chemical compound F[C@H]1[C@H](C2=C(C=CC(=C2[C@H]1F)OC=1C=C(C#N)C=C(C=1)F)S(=O)(=O)C)O LOMMPXLFBTZENJ-ZACQAIPSSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101001054867 Homo sapiens Protein-lysine 6-oxidase Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- ODGXXYXJORZPHE-ZIAGYGMSSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@H]([C@@H](C1)O)F ODGXXYXJORZPHE-ZIAGYGMSSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 229950005450 emitefur Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 2
- 201000000052 gastrinoma Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 102000051318 human LOX Human genes 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 210000000277 pancreatic duct Anatomy 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 229960005569 saridegib Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000005893 serous cystadenoma Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UUBHZHZSIKRVIV-KCXSXWJSSA-N (2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O UUBHZHZSIKRVIV-KCXSXWJSSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- ZPHYPKKFSHAVOE-YZIXBPQXSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-6-methyl-5-[(2r)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 ZPHYPKKFSHAVOE-YZIXBPQXSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DHXXLGDTPFPYRH-WDZFZDKYSA-N (Z)-3-fluoro-4-quinolin-8-ylsulfonylbut-2-en-1-amine Chemical compound C1=C2C(C(=CC=C2)S(=O)(=O)C/C(=C/CN)/F)=NC=C1 DHXXLGDTPFPYRH-WDZFZDKYSA-N 0.000 description 1
- CQBDTOILYHIRIW-TWGQIWQCSA-N (Z)-4-(benzenesulfonyl)-3,4,4-trifluorobut-2-en-1-amine Chemical compound C1=CC=CC(=C1)S(=O)(=O)C(F)(/C(=C/CN)/F)F CQBDTOILYHIRIW-TWGQIWQCSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- VJCVKWFBWAVYOC-UIXXXISESA-N 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea (Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N VJCVKWFBWAVYOC-UIXXXISESA-N 0.000 description 1
- PWSRWJMEGVKWES-WPTDRQDKSA-N 1-[(Z)-4-amino-2-fluorobut-2-enyl]-3-[3-(dimethylsulfamoyl)phenyl]-2-methylindole-5-carboxylic acid hydrochloride Chemical compound Cl.CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)n(C\C(F)=C\CN)c2ccc(cc12)C(O)=O PWSRWJMEGVKWES-WPTDRQDKSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QGBBBLPWBSWERZ-UHFFFAOYSA-N 2-[4-(1-adamantyl)phenoxy]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)COC1=CC=C(C23CC4CC(CC(C4)C2)C3)C=C1 QGBBBLPWBSWERZ-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- AQLUWRRQWYYZBA-UHFFFAOYSA-N 2-amino-5-methyl-5-sulfanylhexanoic acid Chemical compound CC(C)(S)CCC(N)C(O)=O AQLUWRRQWYYZBA-UHFFFAOYSA-N 0.000 description 1
- IZQAUUVBKYXMET-UHFFFAOYSA-N 2-bromoethanamine Chemical compound NCCBr IZQAUUVBKYXMET-UHFFFAOYSA-N 0.000 description 1
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical compound NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 1
- VZUKEVFHSPMCSH-UHFFFAOYSA-N 2-nitroethanamine Chemical compound NCC[N+]([O-])=O VZUKEVFHSPMCSH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- INSNGJNTNAUITD-ULPVBNQHSA-N 3-[1-[(Z)-4-amino-2-fluorobut-2-enyl]-2-methylpyrrolo[3,2-b]pyridin-3-yl]-N,N-dimethylbenzenesulfonamide dihydrochloride Chemical compound Cl.Cl.CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)n(C\C(F)=C\CN)c2cccnc12 INSNGJNTNAUITD-ULPVBNQHSA-N 0.000 description 1
- JXEICPOBKSQAIU-UHFFFAOYSA-N 3-bromo-1-[12-(3-bromopropanoyl)-3,12-diaza-6,9-diazoniadispiro[5.2.5^{9}.2^{6}]hexadecan-3-yl]propan-1-one Chemical compound C1CN(C(=O)CCBr)CC[N+]21CC[N+]1(CCN(CC1)C(=O)CCBr)CC2 JXEICPOBKSQAIU-UHFFFAOYSA-N 0.000 description 1
- ZTGQZSKPSJUEBU-UHFFFAOYSA-N 3-bromopropan-1-amine Chemical compound NCCCBr ZTGQZSKPSJUEBU-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- GIGCDIVNDFQKRA-LTCKWSDVSA-N 4-[(2s)-2-amino-2-carboxyethyl]-n,n-bis(2-chloroethyl)benzeneamine oxide;dihydrochloride Chemical compound Cl.Cl.OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])(CCCl)CCCl)C=C1 GIGCDIVNDFQKRA-LTCKWSDVSA-N 0.000 description 1
- PNAWUIKCVQSLFG-UHFFFAOYSA-N 4-[(4-chloro-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]-2,6-difluorobenzoic acid Chemical compound C1=C2C(C)(C)CCC(C)(C)C2=C(Cl)C(O)=C1C(=O)NC1=CC(F)=C(C(O)=O)C(F)=C1 PNAWUIKCVQSLFG-UHFFFAOYSA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- VVTNSTLJOVCBDL-UHFFFAOYSA-N 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid Chemical compound C[Si](C)(C)C1=CC([Si](C)(C)C)=CC(C(=O)NC=2C=CC(=CC=2)C(O)=O)=C1 VVTNSTLJOVCBDL-UHFFFAOYSA-N 0.000 description 1
- SZBGQDXLNMELTB-UHFFFAOYSA-N 4-fluoro-n-methyl-n-[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl]-2-(trifluoromethyl)benzamide Chemical compound C=1C=C(F)C=C(C(F)(F)F)C=1C(=O)N(C)C(CC1)CCN1C(C1=CC=CC=C11)=NN=C1C1=CC=NN1C SZBGQDXLNMELTB-UHFFFAOYSA-N 0.000 description 1
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical class C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- XNUNVQKARNSSEO-UHFFFAOYSA-N 6-[4-(1-propan-2-ylpiperidin-4-yl)-1,4-diazepan-1-yl]-n-pyridin-4-ylpyridine-2-carboxamide Chemical compound C1CN(C(C)C)CCC1N1CCN(C=2N=C(C=CC=2)C(=O)NC=2C=CN=CC=2)CCC1 XNUNVQKARNSSEO-UHFFFAOYSA-N 0.000 description 1
- KAEVHZSIYLATMK-UHFFFAOYSA-N 6-n-[bis(aziridin-1-yl)phosphoryl]-2-n,2-n,7-trimethylpurine-2,6-diamine Chemical compound C=12N(C)C=NC2=NC(N(C)C)=NC=1NP(=O)(N1CC1)N1CC1 KAEVHZSIYLATMK-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
- 229940127512 Androgen Synthesis Inhibitors Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 102100021979 Asporin Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- LCFVJGUPQDGYKZ-UHFFFAOYSA-N Bisphenol A diglycidyl ether Chemical compound C=1C=C(OCC2OC2)C=CC=1C(C)(C)C(C=C1)=CC=C1OCC1CO1 LCFVJGUPQDGYKZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100027140 Butyrophilin subfamily 1 member A1 Human genes 0.000 description 1
- 102100027156 Butyrophilin subfamily 2 member A2 Human genes 0.000 description 1
- 102100027155 Butyrophilin subfamily 3 member A2 Human genes 0.000 description 1
- 102100025429 Butyrophilin-like protein 2 Human genes 0.000 description 1
- KFUYFFAUPULPHK-UHFFFAOYSA-O CCS.O[S+]=O Chemical compound CCS.O[S+]=O KFUYFFAUPULPHK-UHFFFAOYSA-O 0.000 description 1
- 102100024263 CD160 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- RURLVUZRUFHCJO-UHFFFAOYSA-N Chromomycin A3 Natural products COC(C1Cc2cc3cc(OC4CC(OC(=O)C)C(OC5CC(O)C(OC)C(C)O5)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC6CC(OC7CC(C)(O)C(OC(=O)C)C(C)O7)C(O)C(C)O6)C(=O)C(O)C(C)O RURLVUZRUFHCJO-UHFFFAOYSA-N 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- BYYRNPIGDRRGLJ-UHFFFAOYSA-N ClC1=CC=C(C=C1)C1=NC(NC(=C1)C1=CC(=C(C=C1)O)OC)=O Chemical compound ClC1=CC=C(C=C1)C1=NC(NC(=C1)C1=CC(=C(C=C1)O)OC)=O BYYRNPIGDRRGLJ-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100021811 E3 ubiquitin-protein ligase RNF5 Human genes 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100038367 Gremlin-1 Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 1
- 101000752724 Homo sapiens Asporin Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000984929 Homo sapiens Butyrophilin subfamily 1 member A1 Proteins 0.000 description 1
- 101000984925 Homo sapiens Butyrophilin subfamily 2 member A2 Proteins 0.000 description 1
- 101000984917 Homo sapiens Butyrophilin subfamily 3 member A2 Proteins 0.000 description 1
- 101000934738 Homo sapiens Butyrophilin-like protein 2 Proteins 0.000 description 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 description 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- RCOVTDPDGVXQIK-UHFFFAOYSA-M O.O.O.[Na+].[O-]S(=O)CCCCS Chemical compound O.O.O.[Na+].[O-]S(=O)CCCCS RCOVTDPDGVXQIK-UHFFFAOYSA-M 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091001451 PEGPH20 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 101710199268 Periostin Proteins 0.000 description 1
- 102100037765 Periostin Human genes 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101710118150 Podoplanin Proteins 0.000 description 1
- 102100037265 Podoplanin Human genes 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 1
- 101710142157 Stanniocalcin-1 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- KGUMXGDKXYTTEY-FRCNGJHJSA-N all-trans-4-hydroxyretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C KGUMXGDKXYTTEY-FRCNGJHJSA-N 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical class OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 229950008343 amsilarotene Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 229940070199 belzutifan Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- DCBILZQETXFXAY-UHFFFAOYSA-N butane-1-sulfinic acid Chemical compound CCCCS(O)=O DCBILZQETXFXAY-UHFFFAOYSA-N 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229950009537 epristeride Drugs 0.000 description 1
- 229940014684 erivedge Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- KPEUDULLQDHKAZ-VROINQGHSA-N ethinylestradiol sulfonate Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OS(=O)(=O)C(C)C)=CC=C3[C@H]21 KPEUDULLQDHKAZ-VROINQGHSA-N 0.000 description 1
- 229950001118 ethinylestradiol sulfonate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- SFNSLLSYNZWZQG-VQIMIIECSA-N glasdegib Chemical compound N([C@@H]1CCN([C@H](C1)C=1NC2=CC=CC=C2N=1)C)C(=O)NC1=CC=C(C#N)C=C1 SFNSLLSYNZWZQG-VQIMIIECSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960003648 ixazomib Drugs 0.000 description 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 1
- 229950010248 loretin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229960000667 mepartricin Drugs 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- ALPPGSBMHVCELA-WHUUVLPESA-N methyl (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-7-oxoheptan-2-yl]-1,3,5,7,9,13,37-heptahydroxy-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate methyl (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,7,9,13,37-heptahydroxy-17-[5-hydroxy-7-[4-(methylamino)phenyl]-7-oxoheptan-2-yl]-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate Chemical compound CC1\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C(O[C@H]2[C@H]([C@@H](N)[C@H](O)[C@@H](C)O2)O)CC(O2)C(C(=O)OC)C(O)CC2(O)CC(O)CC(O)CC(O)CC(O)CC(=O)CC(O)CC(=O)OC1C(C)CCC(O)CC(=O)C1=CC=C(N)C=C1.C1=CC(NC)=CC=C1C(=O)CC(O)CCC(C)C1C(C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(O[C@H]2[C@H]([C@@H](N)[C@H](O)[C@@H](C)O2)O)CC(O2)C(C(=O)OC)C(O)CC2(O)CC(O)CC(O)CC(O)CC(O)CC(=O)CC(O)CC(=O)O1 ALPPGSBMHVCELA-WHUUVLPESA-N 0.000 description 1
- 190000032366 miboplatin Chemical compound 0.000 description 1
- 229950002777 miboplatin Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940024847 odomzo Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229950002575 patidegib Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 229950010307 peretinoin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229940034049 polysaccharide-k Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 229950000989 procodazole Drugs 0.000 description 1
- XYWJNTOURDMTPI-UHFFFAOYSA-N procodazole Chemical compound C1=CC=C2NC(CCC(=O)O)=NC2=C1 XYWJNTOURDMTPI-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229950007401 pumitepa Drugs 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003349 semicarbazides Chemical class 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005325 sonidegib Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095374 tabloid Drugs 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- JXLYSJRDGCGARV-CUGARIAGSA-N vinblastine Chemical compound C([C@@](C1)(O)CC)C(C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 JXLYSJRDGCGARV-CUGARIAGSA-N 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
- G01N2474/20—Immunohistochemistry assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to a method for selecting a cancer patient for which a combination therapy of a retinoid and a cancer therapeutic agent is effective, and a drug for which a retinoid and a cancer therapeutic agent are effective for the selected cancer patient.
- Stroma is a general term for cancer-related fibroblasts, extracellular matrix, immune cells, blood vessels, etc. that make up the microenvironment of cancer.
- malignant tumors such as pancreatic cancer (sometimes referred to as “pancreatic tumor"), bile duct cancer, breast cancer, lung cancer, etc.
- this stroma is abundant, causing resistance to anticancer drug treatment. I've been told.
- Cancer-related fibroblasts which are the main components of the stroma, promote the growth of cancer cells by various mechanisms, and the abundant extracellular matrix derived from cancer-related fibroblasts is an anticancer agent. It was thought to be a cancer-promoting factor because it hindered the penetration of cancer. Therefore, an attempt was made to treat cancer by targeting cancer-related fibroblasts, but unexpectedly, highly malignant cancer cells were generated (Non-Patent Document 1).
- cancer-suppressing cancer-related fibroblasts also exist, and the GPI-anchored type is used as a specific molecular marker.
- Meflin a membrane molecule, has been identified (Non-Patent Documents 2-4).
- cancer-suppressing cancer-related fibroblasts are transformed (transformed) into cancer-promoting cancer-related fibroblasts, while cancer-promoting by specific drugs. It was revealed that cancer-related fibroblasts can also return (reprogram) to cancer-suppressing cancer-related fibroblasts.
- ATRA all-trans retinoic acid
- vitamin D is known as a drug for reprogramming cancer-promoting cancer-related fibroblasts into cancer-suppressing cancer-related fibroblasts (non-patent literature). 5-9).
- the present invention provides a highly effective cancer therapeutic drug to a cancer patient having a malignant tumor with many anticancer drug treatment-resistant stroma, and selects a cancer patient for which treatment using the drug is effective.
- the challenge is to provide a way to do this.
- the present invention includes the following inventions in order to solve the above problems.
- Method. [3]
- the step of selecting a cancer patient is to prepare a histopathological specimen of malignant tumor tissue obtained from a test cancer patient and detect at least one cancer-related fibroblast under microscopic observation.
- the step of selecting a cancer patient is to observe a histopathological specimen of malignant tumor tissue obtained from a test cancer patient under a microscope, and in an arbitrary strongly magnified field including a cancer cell region and an interstitial region.
- the cancer therapeutic agent is a chemotherapeutic agent, a molecular target agent, an immunotherapeutic agent or a hormone therapeutic agent.
- the cancer therapeutic agent is a chemotherapeutic agent, a molecular target agent, an immunotherapeutic agent or a hormone therapeutic agent.
- the pharmaceutical according to the above [11] or [12], wherein the retinoid is tamibarotene.
- a drug for enhancing the action of a drug is a drug for enhancing the action of a drug.
- the drug according to the above [14], wherein the composition for overexpressing mephrin is a viral vector containing a mephrin gene.
- [17] A drug for inducing suppression of lysyl oxidase activity in the interstitium of cancer and a cancer therapeutic drug for cancer patients selected by the method according to any one of [1] to [6] above.
- the cancer therapeutic agent is a chemotherapeutic agent, a molecular target agent, an immunotherapeutic agent or a hormone therapeutic agent.
- a drug that induces suppression of the activity of lysyl oxidase in the interstitium of cancer is used in advance.
- the active ingredient is a drug that induces suppression of lysyloxidase activity in the interstitium of cancer.
- the cancer therapeutic agent is a chemotherapeutic agent, a molecular target agent, an immunotherapeutic agent or a hormone therapeutic agent.
- the present invention it is possible to provide a highly effective cancer therapeutic drug for a cancer patient having a malignant tumor having many anticancer drug treatment-resistant stroma.
- a method for selecting a cancer patient for whom treatment using the drug is effective it is possible to identify a cancer patient with a high therapeutic effect and treat only the selected cancer patient, so that a high medical cost is paid to the cancer patient with a low therapeutic effect and a wasteful treatment is performed. Can be avoided.
- pancreatic tumor acinar cell carcinoma
- pancreatic tumors intrapancreatic papillary mucosal adenocarcinoma (non-invasive cancer)
- Example 6 the tumor was excised 22 days after transplantation to prepare a tissue section, and the expression of the mephrine gene (Islr) in the tumor was detected by in situ hybridization (ISH).
- ISH in situ hybridization
- B is a typical microscopic image of the 3 mg / kg / day group of AM80
- C is a dot of the Islr positive signal per strongly magnified field of view of both groups. It is a figure which compares numbers.
- the tumor was excised 22 days after transplantation to prepare a tissue section, and the expression of the actin gene (Acta2) in the tumor was detected by in situ hybridization (ISH).
- (A) ) Is a representative microscopic image of the control group
- (B) is a typical microscopic image of the 3 mg / kg / day group of AM80
- (C) is a dot of Acta2 positive signal per strongly magnified field of view of both groups. It is a figure which compares numbers.
- the tumor was excised 22 days after transplantation to prepare a tissue section, immunostained with an anti-CD31 antibody, and the vascular lumen area was measured.
- (A) is a control group.
- (B) is a representative microscopic image of AM80 in the 3 mg / kg / day group
- (C) is a diagram comparing the lumen lumen areas of both groups. It is a figure which shows the protocol of Example 7.
- Example 11 It is a figure which shows the result of having measured the tumor volume after transplantation of each group with time in Example 11 using a mephrin-deficient mouse.
- the tumor was excised 24 days after transplantation to prepare a tissue section, and the expression of the actin gene (Acta2) in the tumor was detected by in situ hybridization (ISH).
- ISH in situ hybridization
- Example 12 shows the protocol of Example 12.
- Sendai virus (SeV-Meflin) that overexpresses mephrine in infected cells
- Sendai virus (SeV-GFP) that overexpresses GFP in infected cells
- ISH in situ hybridization
- Example 12 is a representative microscopic image of the group to which SeV-GFP was administered, and (B) is a typical microscopic image of the group to which SeV-Meflin was administered.
- Example 12 it is a figure which compares the tumor volume of both groups 17 days after transplantation. It is a figure which shows the protocol of Example 13.
- Example 13 using mice subcutaneously transplanted with mouse pancreatic cancer cells, gemcitabine was further added to the group in which SeV-Meflin was intratumorally administered and then gemcitabine was further administered, and the group in which SeV-GFP was intratumorally administered. It is a figure which compares the tumor volume of the administration group on the 17th day after transplantation.
- Typical second harmonic microscopic observation image of the type KPC group (B) is a typical second harmonic microscopic observation image of the mephrin-deficient KPC group, and (C) is the curvature (linearity) of collagen in both groups. It is a figure comparing. It is a figure which shows the result of having administered tamibarotene or a solvent (DMSO) to a mouse subcutaneously transplanted with mouse pancreatic cancer cells, and measured the collagen arrangement in the tumor stroma with a second harmonic microscope, and (A) is a control group.
- DMSO tamibarotene or a solvent
- Example 17 using mice subcutaneously transplanted with mouse pancreatic cancer cells, a group to which gemcitabine was administered after pre-administration of tamibarotene, a group to which tamibarotene and gemcitabine were co-administered after pre-administration of tamibarotene, and a group instead of tamibarotene.
- Example 18 It is a figure which shows the result of having measured the tumor volume with time of the group to which DMSO and gemcitabine were administered. It is a figure which shows the protocol of Example 18. Results of measuring the tumor volume over time in the group to which the anti-PD-L1 antibody was administered and the group to which the anti-PD-L1 antibody and tamibarotene were administered in Example 18 using mice subcutaneously transplanted with mouse pancreatic cancer cells. It is a figure which shows. In Example 18, it is a figure which shows the transition of the survival rate until the death of all the mice of both groups. It is a figure which shows the protocol of Example 19.
- Example 19 using mice subcutaneously transplanted with mouse pancreatic cancer cells, the tumor volume of the anti-PD-L1 antibody-administered group, the anti-PD-L1 antibody and tamibarotene-administered group, and the IgG-administered control group. It is a figure which shows the result of having measured with time. In Example 19, it is a figure which shows the transition of the survival rate until the death of all the mice of the whole group. It is a figure which shows the protocol of Example 20.
- Example 20 Results of measuring the tumor volume over time in the group to which the anti-PD-L1 antibody was administered and the group to which the anti-PD-L1 antibody and tamibarotene were administered in Example 20 using mice subcutaneously transplanted with mouse bladder cancer cells. It is a figure which shows. In Example 19 using mice subcutaneously transplanted with mouse lung cancer cells, the results of measuring the tumor volume over time in the group to which the anti-PD-L1 antibody was administered and the group to which the anti-PD-L1 antibody and tamibarotene were administered are shown. It is a figure. It is a figure which shows the protocol of Example 23.
- Example 23 using a mephrin-deficient mouse subcutaneously transplanted with mouse pancreatic cancer cells, a group to which the anti-PD-L1 antibody was administered, a group to which the anti-PD-L1 antibody and tamibarotene were administered, and a control group to which IgG was administered. It is a figure which shows the result of having measured the tumor volume with time. In Example 23, it is a figure which shows the transition of the survival rate until the death of all the mice of the whole group.
- the present invention provides a drug for treating cancer, which is administered in combination with a retinoid and a therapeutic drug for cancer (hereinafter referred to as "the first drug of the present invention").
- the subject of administration of the first drug of the present invention is a cancer patient having a malignant tumor with infiltration of cancer-related fibroblasts in the stroma. Cancer patients with malignant tumors with infiltration of cancer-related fibroblasts in the stroma can be selected by the methods described below. Also included in the present invention is a method of selecting a cancer patient for whom such combination therapy of a retinoid and a cancer therapeutic agent is effective.
- the method for selecting a cancer patient for which combination therapy of retinoid and a cancer therapeutic agent is effective (hereinafter referred to as "the method for selecting a cancer patient of the present invention") is to infiltrate cancer-related fibroblasts into the stroma.
- the step of selecting a cancer patient with a malignant tumor associated with is to select at least one cancer-associated fibroblast (hereinafter abbreviated as "CAF") in the malignant tumor tissue obtained from the test cancer patient. Any step may be performed including detection.
- the malignant tumor tissue may be one obtained by biopsy or may be obtained by surgery as long as it is a malignant tumor tissue obtained from a test cancer patient.
- a histopathological specimen may be prepared from a malignant tumor tissue obtained from a test cancer patient, a cell suspension may be prepared, or a cell disruption solution may be prepared.
- the means for detecting CAF is not particularly limited, and may be one that detects a CAF-specific nucleic acid, one that detects a CAF-specific protein, or one that detects a CAF-specific morphology.
- a histopathological specimen of malignant tumor tissue obtained from a test cancer patient is prepared. , May include detecting at least one CAF under microscopic observation.
- the method for preparing the histopathological specimen is not particularly limited, and a known method can be appropriately selected depending on the staining method or the detection method to be used. Microscopic observation may be performed over the entire area of the histopathological specimen, and if at least one CAF is detected in the microscopic observation, the test patient is considered to be a cancer patient to whom administration of the first drug of the present invention is effective. You can choose.
- test patient When a plurality of histopathological specimens are prepared, if at least one CAF is detected in any of the histopathological specimens, the test patient is regarded as a cancer patient for whom administration of the first drug of the present invention is effective. You can choose.
- the histopathological specimen of the malignant tumor tissue obtained from the test cancer patient is observed under a microscope.
- the step may include detecting one or more CAFs in any strongly magnified field including a cancer cell region and an interstitial region.
- the number of CAFs in one strongly magnified field of view may be at least one, even if it is 2, 3, 4, 5, 6, 7, 8, 9, 9, or 10 or more. good.
- "High-power field" in microscopic observation means observing at 400x using a 40x objective lens and a 10x eyepiece, and is also called a high-power field (HPF).
- CAF may be detected by staining the histopathological specimen with Hematoxylin Eosin (hereinafter, may be abbreviated as "HE staining").
- HE staining Hematoxylin Eosin
- a pathologist usually observes the HE-stained specimen under a microscope to morphologically determine the presence or absence of CAF.
- a method of detecting a CAF marker molecule by immunohistochemistry (hereinafter, may be abbreviated as “IHC”) may be used, and the CAF marker molecule may be detected in situ.
- a method of detecting by hybridization (hereinafter, may be abbreviated as "ISH") may be used.
- IHC an IHC sample can be prepared according to a conventional method using an antibody that specifically binds to a marker molecule of CAF.
- ISH specimens can be prepared according to a conventional method using a probe that specifically hybridizes to the mRNA of the marker molecule of CAF.
- the marker molecules for CAF include ⁇ -smooth muscle actin ( ⁇ SMA), meflin, fibroblast activation protein (FAP), platelet-derived growth factor receptor ⁇ (PDGFR ⁇ ), platelet-derived growth factor receptor ⁇ (PDGFR ⁇ ), and fibroblast.
- ⁇ SMA smooth muscle actin
- FAP fibroblast activation protein
- PDGFR ⁇ platelet-derived growth factor receptor ⁇
- PDGFR ⁇ platelet-derived growth factor receptor ⁇
- FSP1 specificprotein1
- Probes that hybridize to these marker molecules in an mRNA-specific manner can be produced by a known method based on the base sequence of the gene encoding these marker molecules.
- the base sequences of the genes encoding these marker molecules can be obtained from known databases (NCBI, etc.).
- Examples of the retinoid used in the first drug of the present invention include acitretinoin, adapalene, AGN194204 (also referred to as IRX4204, NRX194204, VTP194204), AGN195183, and alitretinoin (9-cis-Retinoic).
- amsilarotene amsilarotene, AM580, bexarotene, Bisphenol A diglycidyl ether (also called BADGE), fenretinide, 4-Hydroxyretinoic acid, Isotretinoin (also known as 13-cis-Retinoic acid), LG268, LGD1550, peretinoin, Retinylacetate, tamibarotene (also known as AM80), tazarotene, tretinoin Transretinoic acid (ATRA)), TTNPB, etc. can be mentioned.
- retinoid includes “vitamin A derivative”, “vitamin A analog”, “retinoic acid receptor (RAR) agonist” and “retinoic X receptor (RXR) agonist”, and “retinoic acid”. It does not include “acid receptor (RAR) antagonists” and “retinoic X receptor (RXR) antagonists”.
- the retinoid may form a salt, and the salt is preferably a pharmaceutically acceptable salt.
- a pharmaceutically acceptable salt for example, hydrochloric acid, sulfuric acid, lactic acid, tartaric acid, maleic acid, fumaric acid, oxalic acid, malic acid, citric acid, oleic acid, palmitic acid, nitrate, phosphoric acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid, p- Salts with acids such as toluene sulfonic acid; salts with alkali metals or alkaline earth metals such as sodium, potassium, calcium, or with hydroxides or carbonates of aluminum; triethylamine, benzylamine, diethanolamine, t-butylamine, Examples thereof include salts with dicyclohexylamine, arginine and the like.
- the present inventors improve the delivery of retinoids to malignant tumors associated with infiltration of CAF into the stroma of the concomitant cancer therapeutic agent, thereby that the cancer therapeutic agent is used. It has been found to enhance the action. Therefore, it can be said that the retinoid is an active ingredient of a drug for enhancing the action of a cancer therapeutic drug used in combination. In addition, it can be said that the retinoid is an active ingredient of a drug for promoting delivery of a concomitant cancer therapeutic drug to a target tumor tissue.
- the present invention includes a drug for enhancing the action of a cancer therapeutic agent, which comprises a retinoid as an active ingredient, for a cancer patient having a malignant tumor with infiltration of CAF in the stroma. Further, the present invention includes a drug for promoting delivery of a cancer therapeutic agent to a target tumor tissue, which comprises a retinoid as an active ingredient, for a cancer patient having a malignant tumor with CAF infiltration in the stroma. Is done.
- the retinoid used in the first pharmaceutical product of the present invention is appropriately blended with a pharmaceutically acceptable carrier or additive according to a method known as a method for producing a pharmaceutical preparation (for example, the method described in the Japanese Pharmacopoeia).
- a pharmaceutical preparation for example, the method described in the Japanese Pharmacopoeia.
- Troches suppositories, liquids, emulsions, suspensions, release-controlled preparations (eg, immediate-release preparations, sustained-release preparations, sustained-release microcapsules, etc.), aerosols, film preparations (eg, orally disintegrating film).
- release-controlled preparations eg, immediate-release preparations, sustained-release preparations, sustained-release microcapsules, etc.
- aerosols eg, orally disintegrating film.
- Oral mucosa patch film, etc. Injection (eg, subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, etc.), drip, transdermal absorption type preparation, ointment, lotion, patch , Suppositories (for example, anal suppositories, vaginal suppositories, etc.), pellets, nasal agents, pulmonary agents (inhalants), oral agents such as eye drops, or parenteral agents.
- the blending ratio of the carrier or the additive can be appropriately set based on the range usually adopted in the pharmaceutical field.
- the carriers or additives that can be blended are not particularly limited, but various carriers such as water, physiological saline, other aqueous solvents, aqueous or oily bases; excipients, binders, pH adjusters, disintegrants, absorption promoters, etc. Examples thereof include various additives such as agents, lubricants, colorants, flavoring agents, and fragrances.
- Additives that can be mixed with tablets, capsules, etc. include, for example, gelatin, cornstarch, tragant, binders such as gum arabic, excipients such as crystalline cellulose, cornstarch, gelatin, arginic acid and the like. Swelling agents, lubricants such as magnesium stearate, sweeteners such as sucrose, lactose or saccharin, flavors such as peppermint, reddish oil or cherry are used.
- the dispensing unit form is a capsule, the above-mentioned type of material can further contain a liquid carrier such as oil and fat.
- Aseptic compositions for injection can be prepared according to conventional formulation procedures (eg, dissolving or suspending the active ingredient in a solvent such as water for injection, natural vegetable oil, etc.).
- aqueous solution for injection for example, a physiological saline solution, an isotonic solution containing glucose and other auxiliary agents (for example, D-sorbitol, D-mannitol, sodium chloride, etc.) and the like are used, and an appropriate solubilizing agent, for example, is used. It may be used in combination with alcohol (ethanol, etc.), polyalcohol (propylene glycol, polyethylene glycol, etc.), nonionic surfactant (polysorbate 80, HCO-50, etc.).
- oily liquid for example, sesame oil, soybean oil and the like are used, and may be used in combination with benzyl benzoate, benzyl alcohol and the like as solubilizing agents.
- buffers eg phosphate buffer, sodium acetate buffer, etc.
- soothing agents eg, benzalkonium chloride, procaine hydrochloride, etc.
- stabilizers eg, human serum albumin, polyethylene glycol, etc.
- preservatives eg, human serum albumin, polyethylene glycol, etc.
- it may be blended with benzyl alcohol, phenol, etc.), an antioxidant, or the like.
- Retinoids are less toxic to humans and other mammals (eg, rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.) and can be safely administered.
- the content of retinoid in the preparation varies depending on the dosage form, administration method, carrier, etc., but is usually 0.01 to 100% (w / w) with respect to the total amount of the preparation, and is 0.1 to 95% (w / w). It may be a ratio.
- the dose of retinoid varies depending on the subject, symptoms, administration route, etc., but in the case of oral administration, for example, in a human with a body weight of about 60 kg, about 0.01 to 1000 mg, preferably about 0.1 to 100 mg per day, More preferably, it is about 0.5 to 500 mg.
- the single dose varies depending on the patient's condition, symptoms, administration method, etc., but for example, in the case of injection, it is usually about 0.01 to 1000 mg, preferably about 0.01 to 500 mg per 1 kg of body weight. More preferably, about 0.01 to 20 mg is administered intravenously.
- the total daily dose may be a single dose or a divided dose.
- the cancer therapeutic agent used in the first drug of the present invention is not particularly limited, but for example, a chemotherapeutic agent, an immunotherapeutic agent or a hormone therapeutic agent is preferable. These cancer therapeutic agents may be liposome preparations. Further, these cancer therapeutic agents may be nucleic acid drugs or antibody drugs.
- the chemotherapeutic agent is not particularly limited, and is, for example, nitrogenmastered, nitrogenmastered hydrochloride-N-oxide, chlorambutyl, cyclophosphamide, iposfamide, thiotepa, carbocon, improsulfan tosylate, busulfan, nimustin hydrochloride, mitobronitol.
- Methotrexate Pemetrexed, Enocitabin, Citarabin, Citarabin octofostate, Ansitabin hydrochloride, 5-FU drugs (eg, fluorouracil, Tegafur, UFT, Doxyflulysine, Carmofur, Galocitabin, Emitefur, Capecitabin, etc.)
- Antimetabolites such as, tabloid, butosine, forinate calcium, levofolinate calcium, cladribine, emitefur, fludalabine, gemcitabine, hydroxycarbamide, pentostatin, pyritrexim, idoxyuridine, mitguazone, thiazofulin, ambamustin, bendamstin; for example, actinomycin D.
- Actinomycin C Mitomycin C, Chromomycin A3, Breomycin Hydrochloride, Breomycin Sulfate, Peplomycin Sulfate, Daunorubicin Hydrochloride, Doxorubicin Hydrochloride, Acralvisin Hydrochloride, Pirarubicin Hydrochloride, Epirubicin Hydrochloride, Neocultinostatin, Misramycin, Zarkomycin, Cartinophylline, Anticancer antibiotics such as mitotan, sorbicin hydrochloride, mitoxanthron hydrochloride, idarubicin hydrochloride; for example, etoposide, etoposide phosphate, vinblastin sulfate, bincristin sulfate, bindesin sulfate, teniposide, paclitaxel, docetaxel, binorelbin, irinotecan, irinotecan hydrochloride. Derived from plants such as
- Molecular-targeted drugs are not particularly limited, but are, for example, afatinib, erlotinib, gefitinib, cetuximab, panitzumumab, necitsumumab, crizotinib, rectinib, rapatinib, trastuzumab, trastuzumab, emtancin, trastuzumab, trastuzumab , Temusirolimus, Shirolimus, Imatinib, Dasatinib, Nilotinib, Bostinib, Ponatinib, Ibritumomab Chiukisetan, Ofatumumab, Rituximab, Brentuximab Bedotin, Gemutuximab Ozogamuri , bortezomib, lenvatinib, vandetanib, Serichinibu, Iburuchinibu, Oshimeruchinibu, carfilzom
- the immunotherapeutic agent is not particularly limited, and is, for example, pisibanil, crestin, cizophyllan, lentinan, ubenimex, interferon, interleukin, macrophage colony stimulating factor, granulocyte colony stimulating factor, erythropoietin, phosphotoxin, BCG vaccine, corynebacterium.
- Examples include parbum, levamisol, polysaccharide K, procodazole, ipilimumab, tremelimumab, nivolumab, pembrolizumab, spartarizumab, semiplimab, avelumab, atezolizumab, and durvalumab.
- the immunotherapeutic agent may be an immune checkpoint inhibitor.
- Target molecules of immune checkpoint inhibitors include, for example, CTLA-4, PD-1, LAG-3, BTLA, KIR, TIM-3, PD-L1, PD-L2, B7-H3, B7-H4, HVEM. , GAL9, CD160, VISTA, BTNL2, TIGIT, PVR, BTN1A1, BTN2A2, BTN3A2, CSF-1R, etc.
- the target molecule of the immune checkpoint inhibitor may be CTLA-4, PD-1 or PD-L1.
- Anti-CTLA-4 antibody includes ipilimumab, tremelimumab, etc.
- anti-PD-1 antibody includes nivolumab, pembrolizumab, spartarizumab, semiprimumab, etc.
- anti-PD-L1 antibody includes avelumab, atezolizumab, durvalumab, etc. And so on.
- the hormone therapeutic agent is not particularly limited, and for example, phosfestol, diethylstilbestrol, chlorotrianisen, medroxyprogesterone acetate, megestrol acetate, chlormaginone acetate, ciproterone acetate, danazole, allylestradiol, guestlinone, etc.
- Mepartricin, laroxifene, olmeroxyphene, levormeroxyphene, anti-estrogens eg tamoxifen citrate, tremiphen citrate, etc.
- pills mepitiostane, testrolactone, aminoglutetiimide, LH-RH agonists (eg goselelin acetate, etc.) Buserelin, leuprorelin, etc.), droroxyfen, epithiostanol, ethinyl estradiol sulfonate, aromatase inhibitors (eg, fadrazole hydrochloride, anastrosol, retrozol, exemethan, borozole, formestan, etc.), anti-androgens (eg, flutamid).
- fadrazole hydrochloride anastrosol, retrozol, exemethan, borozole, formestan, etc.
- anti-androgens eg,
- Bicalutamide, niltamide, etc. Bicalutamide, niltamide, etc.
- 5 ⁇ -reductase inhibitors eg, finasteride, epristeride, etc.
- corticohormonal agents eg, dexamethasone, prednisolone, betamethasone, triamsinolone, etc.
- androgen synthesis inhibitors eg, avilateron, etc.
- the retinoid and the cancer therapeutic agent used in the first drug of the present invention may be administered to the administration target at the same time or at different times.
- the term "administered in combination” means that the retinoid is applied at the same time as the cancer therapeutic agent is applied at the same time, and it is not necessary to administer the retinoid at the same time.
- the time difference between the start of retinoid administration and the start of cancer treatment is not particularly limited, but the time difference is 1 day or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more. There may be.
- the dose of the cancer therapeutic agent may be based on the clinically used dose, and may be appropriately selected depending on the administration target, the age and weight of the administration target, the symptoms, the administration time, the dosage form, the administration method, the combination and the like. be able to.
- the present invention provides a drug for enhancing the action of a cancer therapeutic drug, which comprises a composition for overexpressing mephrine in cells of a tumor tissue as an active ingredient (hereinafter, referred to as "second drug of the present invention").
- the subject to which the second drug of the present invention is administered is a cancer patient having a malignant tumor with infiltration of CAF in the stroma, which is the same as the subject to which the first drug of the present invention is administered. Therefore, the administration target of the second drug of the present invention can be selected by the above-mentioned cancer patient selection method of the present invention.
- compositions for overexpressing mephrine in the cells of the tumor tissue a composition containing a plasmid vector in which a DNA encoding mephrin is expressively inserted, a viral vector, or the like can be preferably used.
- the base sequence of the gene encoding mephrin can be easily obtained from a known database (NCBI, etc.).
- the accession number of the base sequence of the human mephrine gene (ISLR) is NM_201526.2 or NM_005545.4.
- a plasmid vector or viral vector expressing mephrin can be prepared by using a known genetic engineering technique based on the obtained nucleotide sequence of the human mephrin gene (ISLR).
- a method for introducing a mephrin expression plasmid using liposomes lipocytosis method, HVJ-lipocytosis method, cationic liposome method, lipofection).
- lipofectamine method, etc. microinjection method, method of transferring mephrin expression plasmid into cells together with carriers (metal particles) with a gene gun (Gene Gun), etc.
- Gene Gun Gene gun
- a viral vector When administered in the form of a viral vector, it can be applied to DNA or RNA viruses such as detoxified retrovirus, adenovirus, adeno-associated virus, herpesvirus, vaccinia virus, poxvirus, poliovirus, Sindobis virus, Sendai virus, SV40.
- the mephrin gene can be introduced by introducing a mephrin expression cassette and infecting the target tumor with a viral vector.
- a viral vector containing a mephrine gene is preferable.
- the dose of the composition that overexpresses mephrine in the cells of the tumor tissue is preferably set appropriately in consideration of the type of vector, expression efficiency, tumor size, and the like.
- the second drug of the present invention is a drug for enhancing the action of a cancer therapeutic drug, it is preferably administered in combination with the cancer therapeutic drug.
- the cancer therapeutic agent to be combined is the same as the cancer therapeutic agent used in the first drug of the present invention.
- the present invention provides a drug for treating cancer, which is administered in combination with a drug that induces suppression of the activity of lysyloxidase in the interstitium of cancer and a therapeutic drug for cancer (hereinafter, "the third drug of the present invention”. ").
- the subject to which the third drug of the present invention is administered is a cancer patient having a malignant tumor with infiltration of CAF in the stroma, which is the same as the subject to which the first drug of the present invention is administered. Therefore, the administration target of the third drug of the present invention can be selected by the above-mentioned cancer patient selection method of the present invention.
- Lysyl oxidase (hereinafter referred to as "LOX") is a copper-containing amine oxidase that oxidizes a primary amine substrate into a reactive aldehyde. Lysyl oxidase catalyzes the oxidative deamination of peptidyllysine and hydroxylysine residues in collagen and peptidyllysine residues in elastin and is essential for the formation of extracellular matrix. The resulting peptidyl aldehyde spontaneously condenses and undergoes an oxidative reaction to form the lysine-derived covalent crosslinks required for the normal structural integrity of the extracellular matrix.
- LOX Lysyl oxidase
- the drug that induces the suppression of LOX activity in the interstitium of cancer may be a drug that directly inhibits LOX or a drug that indirectly inhibits LOX.
- examples of the drug that directly inhibits LOX include LOX inhibitors and anti-LOX neutralizing antibodies.
- LOX inhibitors include, for example, antibodies disclosed in WO2011097513 such as suppressuzumab; compounds disclosed in WO2016144703 such as GB2064; disclosed in WO2020024017 such as PXS-5505, PXS-5446, PXS-6302.
- LOX inhibitors also include primary amines that react with the carbonyl group at the active site of lysyloxidase, including those that produce resonance-stabilized products such as the following primary amines after binding to the carbonyl.
- BAPN ⁇ -aminopropionitrile
- 2-nitroethylamine 2-bromoethylamine
- 2-chloroethylamine 2-Saturated or saturated haloamines
- 2-trifluoroethylamine 3-bromopropylamine
- p-halobenzylamine selenohomocysteine lactone.
- LOX inhibitors also include thiolamines such as D-penicillamine, or 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2-acetamidoethyl)).
- thiolamines such as D-penicillamine, or 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2-acetamidoethyl)).
- Dithio) butanoic acid p-2-amino-3-methyl-3-((2-aminoethyl) dithio) butanoic acid, sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)) Dithio)
- Oxidative removal of lysyl and hydroxylysyl residues by its analogs such as butane sulfinate, 2-acetamidoethyl-2-acetamide ethanethiol sulfanate, sodium-4-mercaptobutanesulfinate trihydrate.
- Examples of drugs that indirectly inhibit LOX include drugs that induce the expression of mephrin in cancer-related fibroblasts in the interstitium of malignant tumors.
- mephrin inhibits the activity of LOX (see Example 14).
- the present inventors increased the expression level of the mephrin gene by treating pancreatic stellate cells and mesenchymal stem cells, which are considered to be the cells of origin of CAF, with retinoids (see Examples 4 and 5). It has been confirmed that when retinoid is administered to mice in which pancreatic cancer cells are subcutaneously transplanted to form a tumor, the expression of the mesenchymal gene in the tumor is significantly increased (Example 6).
- the retinoid used in the first drug of the present invention can be suitably used as a drug that indirectly inhibits LOX.
- the retinoid can be carried out in the same manner as the first medicine of the present invention.
- a composition that overexpresses mephrine in the cells of tumor tissue which is the active ingredient of the second drug of the present invention, can also be suitably used as a drug that indirectly inhibits LOX.
- a composition that overexpresses mephrine in the cells of tumor tissue which is the active ingredient of the second drug of the present invention
- a drug that indirectly inhibits LOX include a plasmid vector into which a DNA encoding mephrine is inserted so as to be expressible, a composition containing a viral vector, and the like.
- the composition for overexpressing mephrine in the cells of a tumor tissue is used as the third drug of the present invention, the composition can be carried out in the same manner as the second drug of the present invention.
- LOX is known to have the activity of cross-linking collagen molecules. It is considered that the cross-linking of collagen molecules increases the strength of collagen fibers and hardens the tissue. Therefore, by inhibiting or suppressing the function of LOX in the cancer stroma, the hardening of cancer tissue is suppressed, the tumor blood vessels are dilated, and the delivery of the concomitant cancer therapeutic agent to the tumor is improved. It is thought that the action of cancer therapeutic agents can be enhanced.
- the present inventors refer to this concept as "interstitial conditioning", and believe that the therapeutic effect can be enhanced by administering a cancer therapeutic agent after subjecting the target tumor to "interstitial conditioning" in advance. There is. Therefore, the drug that induces the suppression of LOX activity in the cancer stroma used in the third drug of the present invention can be referred to as a drug having an "interstitial conditioning" action.
- the drug used in the third drug of the present invention that induces suppression of LOX activity in the cancer stroma is an active ingredient of a drug for enhancing the action of a concomitant cancer therapeutic drug, and the concomitant cancer treatment It can be said that it is an active ingredient of a drug for promoting delivery of a drug to a target tumor tissue. Therefore, the present invention is intended for cancer patients having malignant tumors with CAF infiltration in the stroma, and the active ingredient is a drug that induces suppression of lysyloxidase activity in the stroma of the cancer. Includes drugs for enhancing the action of therapeutic agents.
- the present invention is intended for cancer patients having malignant tumors with CAF infiltration in the stroma
- the active ingredient is a drug that induces suppression of lysyloxidase activity in the stroma of the cancer.
- the cancer therapeutic agent used in the third drug of the present invention is the same as the cancer therapeutic agent used in the first drug of the present invention.
- the drug for inducing the suppression of the activity of lysyl oxidase in the interstitium of cancer and the cancer therapeutic drug used in the third drug of the present invention may be administered to the administration target at the same time or with a time lag. May be administered.
- the term "administered in combination” means that the timing of application of a drug that induces suppression of the activity of lysyl oxidase in the interstitium of cancer and the timing of application of a therapeutic drug for cancer overlap at the same time. It does not require administration.
- the third drug of the present invention it is preferable to start the administration of the drug that induces the suppression of the activity of lysyl oxidase in the interstitium of the cancer in advance, and to start the administration of the cancer therapeutic drug with a time lag.
- the time difference between the start of administration of the drug that induces the suppression of lysyl oxidase activity in the cancer stroma and the start of administration of the cancer therapeutic drug is not particularly limited, but 1 day or more, 2 days or more, 3 days or more, 4 days or more, The time difference may be 5 days or more, 6 days or more, and 7 days or more.
- a hyaluronidase preparation such as PEGylated hyaluronan degrading enzyme PEGPH20 disclosed in WO2012012300; 4-methylumbelli disclosed in US20180201640.
- Hypoxia synthesis inhibitors such as ferron (4-methylumbelliferone) derivatives; IPI-926 (Patidegib, Saridegib) disclosed in WO2006026430, Sonidegib (Odomzo) disclosed in WO2007131201, Vismodegib (Erivedge) disclosed in WO2006028958.
- PF-04449913 (Daurismo) disclosed in US2009005416
- LY-2940680 (Taladegib) disclosed in WO2010147917
- NLM-001 disclosed in WO2009107850
- 4SC-208 disclosed in WO2014001464, etc.
- Hogg signal inhibitor derived from stromal cells such as the nucleic acid drug NOX-A12 disclosed in WO2008009437, WO2009019007, WO2012031773, the compound USL-311 disclosed in WO2012049277, WO2016157149, and the compound LIT-927 disclosed in WO2018011376.
- stromal cell-derived factor 1 inhibitor Hypoxia inducible factor such as compound IDF-11774 disclosed in WO2013048164 and compound PX-478 disclosed in WO2005007828. 1-alpha inhibitor); Hypoxia inducible factor 2-alpha inhibitor such as compound PT-2977 (Belzutifan) disclosed in WO2015035223 can be mentioned.
- the present invention also includes such a combination drug of a drug having an “interstitial conditioning” action without LOX inhibition and a cancer therapeutic drug.
- the present invention includes the following inventions.
- a cancer treatment method comprising administering a retinoid and a cancer therapeutic agent in combination to a cancer patient selected by the cancer patient selection method of the present invention.
- the present invention comprises administering to a cancer patient selected by the method for selecting a cancer patient of the present invention in combination with a drug that induces suppression of the activity of lysyloxidase in the interstitium of cancer and a cancer therapeutic drug.
- Cancer treatment method Cancer treatment method.
- a method for enhancing the action of a cancer therapeutic agent which comprises administering a drug that induces suppression of the activity of lysyl oxidase in.
- a retinoid or a drug that induces suppression of the activity of lysyloxidase in the stroma of cancer is administered to a patient selected by the above-mentioned method for selecting a cancer patient according to the above-mentioned method for selecting a cancer patient and receiving a cancer therapeutic drug.
- a method for promoting delivery of a cancer therapeutic agent to a target tumor tissue including the above.
- a retinoid or a drug that induces suppression of the activity of lysyloxidase in a cancer stroma for producing a drug for treating cancer which is selected by the above-mentioned method for selecting a cancer patient of the present invention. Used for patients who have been treated with cancer drugs.
- Example 1 Determination of malignant tumor with infiltration of CAF in the stroma by HE staining
- FIGS. 1 to 4 show examples of pancreatic tumors with CAF infiltration in the stroma of surgical specimens.
- FIG. 1 is anaplastic cancer
- FIG. 2 is intraductal papillary mucinous adenocarcinoma
- FIGS. 3 and 4 are tubular glandular cancers.
- the arrows indicate the positions of the CAFs.
- FIGS. 5 to 14 examples of pancreatic tumors without CAF infiltration in the stroma of surgical specimens are shown in FIGS. 5 to 14.
- 5 and 6 are adenocarcinomas
- FIG. 7 is intrapancreatic papillary mucinous adenoma (non-invasive cancer)
- FIG. 1 is anaplastic cancer
- FIG. 2 is intraductal papillary mucinous adenocarcinoma
- FIGS. 3 and 4 are tubular glandular cancers.
- the arrows indicate the positions of the CAFs.
- FIGS. 5 to 14 examples of pancreatic tumors
- FIG. 8 is intrapancreatic papillary mucinous adenoma (IPMA), and FIG. 9 is mucinous cyst tumor.
- FIG. 10 is a neuroendocrine tumor (G1, insulinoma)
- FIG. 11 is a neuroendocrine tumor (G1, gastrinoma)
- FIG. 12 is a pancreatic intraepithelial neoplastic lesion (PanIN)
- FIG. 13 is a serous cyst adenoma
- the low magnification is 100 times and the high magnification is 200 times.
- FIGS. 15 to 17 show examples of pancreatic tumors with CAF infiltration in the stroma of biopsy specimens.
- FIG. 15 is a tubular adenocarcinoma
- FIG. 16 is an anaplastic cancer
- FIG. 17 is an intraductal papillary mucous adenocarcinoma (invasive cancer).
- FIGS. 18 to 21 examples of pancreatic tumors without CAF infiltration in the stroma of biopsy specimens are shown in FIGS. 18 to 21.
- FIG. 18 is acinar cell carcinoma
- FIG. 19 is a solid pseudopapillary tumor (SPN)
- FIG. 20 is a neuroendocrine tumor
- FIG. 21 is an intraductal papillary mucinous adenoma (IPMA).
- IPMA intraductal papillary mucinous adenoma
- Example 2 Determination of malignant tumor with infiltration of CAF in the stroma by IHC or ISH
- Tissue specimens prepared from tumor tissue obtained by surgery or biopsy are subjected to ISH using an antibody against the CAF marker molecule or an ISH using a probe that hybridizes to the mRNA of the CAF marker molecule and observed under a microscope. Judgment is based on the presence or absence of a positive signal.
- mephrine is adopted as a marker molecule for CAF, and IHC using an anti-mephrin antibody and ISH using a probe that hybridizes to mRNA of the mephrin gene are performed.
- FIGS. 22 and 23 show an example of a mephrin-positive pancreatic tumor
- FIG. 24 shows an example of a mephrin-negative pancreatic tumor.
- Both figures are images obtained by performing IHC and ISH on the same sample, and the high magnification is a strongly magnified field of view (400 times).
- the arrows indicate the location of positive cells.
- the IHC high-magnification image of FIG. 24 it is the non-specific reaction to the necrotic cells that is deeply stained in the round cells.
- Example 3 Tumor shrinkage effect of tamibarotene on malignant tumors with infiltration of CAF in the stroma
- Human pancreatic cancer cells BxPC-3 (1.0 x 10 6 ) are subcutaneously transplanted into BALB / c-nu female nude mice to form a cancer cell single transplant group.
- human pancreatic cancer cells BxPC-3 (1.0 x 10 6 ) and human pancreatic stellate cells (5.0 x 10 6 ) are subcutaneously transplanted into BALB / c-nu female nude mice to form a co-transplant group.
- Pancreatic stellate cells are pancreatic fibroblasts and are considered to be the origin of CAF.
- the cancer cell single transplant group and co-transplant group are divided into two groups, a group to receive gemcitabine (Gem) and tamibarotene (AM80) (Gem + AM80 group) and a group to receive Gem and DMSO (Gem + DMSO group), respectively.
- AM80 (3.0 mg / kg) or DMSO is orally administered daily from the 3rd day to the 14th day after transplantation.
- Gem 50 mg / kg
- Tumor volume is measured 15 days after transplantation.
- the protocol is shown in FIG.
- Example 4 Effect of retinoid reprogramming on human pancreatic stellate cells and mouse mesenchymal stem cells
- the primary human pancreatic stellate cells used are those provided by Dr. Masamune of Tohoku University.
- the primary mouse mesenchymal stem cells used are those purchased from Cyagen Co., Ltd. Both pancreatic stellate cells and mesenchymal stem cells are considered to be the origin cells of CAF.
- the retinoid the retinoid contained in SCREEN-WELL Nuclear Receptor ligand library (ENZO) is used.
- DMEM + 10% FBS is used as the culture medium.
- the cells are seeded in a collagen-coated dish and cultured until they are 100% confluent, and various retinoids are added to a concentration of 1 ⁇ M. After 48 hours, cells are harvested, RNA is extracted using RNeasyPLUS KIT (QIAGEN), and cDNA is synthesized using ReverseTra Ace qPCR RT Master Mix (TOYOBO). The expression level of the mephrine gene (ISLR and Islr) is measured by qPCR using the Gene expression assay (Thermo Fisher scientific).
- Results Table 1 shows the results of primary human pancreatic stellate cells.
- the ISLR expression level is shown as a relative expression level when the ISLR expression level of the control (DMSO-treated cells) is 1. All retinoids used increase ISLR expression.
- the marker for cancer-promoting CAF is ⁇ SMA (gene name: ACTA2)
- the marker for tumor suppressor CAF is mephrin (gene name: ISLR)
- the expression levels of both markers in CAF are inversely proportional. I know. Therefore, this result indicates that retinoids reprogram human cancer-promoting CAFs into cancer-inhibitory CAFs.
- Table 2 shows the results of primary mouse mesenchymal stem cells.
- the Islr expression level is shown as a relative expression level when the Islr expression level of the control (DMSO-treated cells) is 1. All retinoids used increase Islr expression.
- the marker for cancer-promoting CAF is ⁇ SMA (gene name: Acta2)
- the marker for tumor suppressor CAF is mephrin (gene name: Islr)
- the expression levels of both markers in CAF are inversely proportional. I know. Therefore, this result indicates that retinoids reprogram mouse cancer-promoting CAFs into cancer-inhibitory CAFs.
- Example 5 Effect of reprogramming on mouse mesenchymal stem cells
- ATRA, AM80 and AM580 are used as retinoids.
- the expression levels of the mephrine gene (Islr), actin gene (Acta2), type I collagen gene (Col1a1) and type III collagen gene (Col3a1) are measured by qPCR.
- Example 6 Effect of tamibarotene (AM80) on mouse pancreatic cancer cells
- Pancreatic cancer cell mT5 which was distributed by Dr. David Tuveson of Cold Spring Harbor Laboratory, is used.
- mT5 is a pancreatic cancer cell established from a pancreatic tumor that developed in KPC mice, which is a spontaneous model of pancreatic cancer (Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015 Jan 15; 160 (1-2)) : 324-38. Doi: 10.1016 / j.cell.2014.12.021. Epub 2014 Dec 31.).
- AM80 is orally administered to mice with confirmed tumor formation for 15 days.
- AM80 0.1 mg / kg / day, 0.5 mg / kg / day, 1 mg / kg / day, 3 mg / kg / day
- mice were euthanized, tumors were removed, tissue specimens were prepared, and in situ hybridization (ISH) was performed to detect expression of the mephrine gene (Islr) and actin gene (Acta2). Count the number of signals. Furthermore, a tissue specimen of the tumor is prepared, immunostained with an anti-CD31 antibody, and CD31, which is a marker of vascular endothelial cells, is stained to measure the vascular lumen area. The protocol is shown in FIG.
- FIG. 30 shows the results of ISH detection of Islr expression in tumor specimens.
- A is a representative microscopic image of the control group
- B is a typical microscopic image of the AM80 3 mg / kg / day group
- C is a control group and AM80 3 mg / kg / day. It is a figure which compares the number of dots of the Islr positive signal per strongly magnified field (400 times) in a group.
- the expression of Islr, a marker of inhibitory CAF was increased by administration of AM80, and the number of dots of the Islr positive signal in the 3 mg / kg / day group of AM80 was significantly higher than that in the control group.
- FIG. 31 shows the results of ISH detection of Acta2-expressing cells in tumor specimens.
- A is a representative microscopic image of the control group
- B is a typical microscopic image of the AM80 3 mg / kg / day group
- C is a control group and AM80 3 mg / kg / day. It is a figure which compares the number of dots of Acta2 positive signal per strongly magnified field (400 times) in a group.
- the expression of Acta2 a marker of accelerated CAF, was reduced by administration of AM80, and the number of dots of Acta2 positive signal in the 3 mg / kg / day group of AM80 was significantly lower than that in the control group.
- FIG. 32 shows the results of immunostaining of tumor specimens with anti-CD31 antibody.
- A is a representative microscopic image of the control group
- B is a typical microscopic image of the AM80 3 mg / kg / day group
- C is a control group and AM80 3 mg / kg / day. It is a figure which compares the vascular lumen area of a group. The vascular lumen area of the 3 mg / kg / day group of AM80 was significantly higher than that of the control group.
- Example 7 Effect of combined use of tamibarotene and gemcitabine on mouse pancreatic cancer cells
- gemcitabine 50 mg / kg is intraperitoneally administered once each on Day15, Day18, and Day21 to the Gem group and the Gem + AM80 group.
- DMSO is orally administered to the control group instead of tamibarotene, and saline is intraperitoneally administered instead of gemcitabine.
- Tumor volume is measured before the start of AM80 administration (Day8), Day12, Day15, Day18, Day21, and Day24. The protocol is shown in FIG.
- FIG. 34 shows that the Gem group significantly suppresses tumor growth than the control group, and the Gem + AM80 group significantly suppresses tumor growth than the Gem group. This result indicates that tamibarotene significantly enhances the tumor growth inhibitory effect of gemcitabine.
- Example 8 Effect of combined use of tamibarotene, gemcitabine and nabpaclitaxel on human pancreatic cancer cells
- Tamibarotene (3.0 mg / kg) is orally administered to the Gem + nabPTX + AM80 group once daily for 17 days from the grouping day (Day 1).
- gemcitabine 50 mg / kg was intraperitoneally administered once each on Day7, Day10 and Day13
- nabpaclitaxel 5 mg / kg was administered once each on Day7, Day10 and Day13 in the Gem + nabPTX group and Gem + nabPTX + AM80 group.
- DMSO is orally administered instead of tamibarotene
- saline is intraperitoneally administered instead of gemcitabine
- saline is intravenously administered instead of nabupaclitaxel.
- Tumor volume is measured before the start of AM80 administration (Day1), Day4, Day7, Day10, Day13, and Day16. The protocol is shown in FIG.
- Example 9 Effect of combined use of tamibarotene and gemcitabine in a mouse pancreatic cancer spontaneous onset model (KPC mouse)]
- KPC mouse Mouse pancreatic cancer spontaneous onset model (KPC mouse) (SR Hingorani et al., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005) From the time when it was confirmed by abdominal echo examination that the pancreatic tumor major axis became 1 mm or more (Day 1), tamibarotene (3.0 mg / kg) was orally administered once a day for 17 days.
- gemcitabine (50 mg / kg) is intraperitoneally administered once each on Day 7, Day 10 and Day 13, but tamibarotene is not administered.
- the tumor major axis is measured before the start of AM80 administration (Day1), Day8, Day15, and Day22. The protocol is shown in FIG. 37.
- FIG. 38 shows that the Gem + AM80 group significantly suppresses tumor growth than the control group (Gem group).
- KPC mice have more abundant stroma with infiltration of CAF and are the closest mouse model to human pancreatic tumors. It is shown that tamibarotene significantly enhances the tumor growth inhibitory effect of gemcitabine in this spontaneous model.
- Example 10 Effect of combined use of tamibarotene and immune checkpoint inhibitor in a mouse pancreatic cancer spontaneous onset model (KPC mouse)]
- KPC mouse pancreatic cancer spontaneous onset model
- Example 11 Effect of combined use of tamibarotene and gemcitabine in mice lacking mephrine]
- Tamibarotene (3.0 mg / kg) is orally administered to the Gem + AM80 group once daily for 17 days from Day 8.
- Gemcitabine 50 mg / kg is intraperitoneally administered once each on Day15, Day18, and Day21 in the Gem group and Gem + AM80 group.
- Body weight and tumor volume will be measured before the start of AM80 administration (Day8), Day12, Day15, Day18, Day21, and Day24.
- mice are euthanized, tumors are removed, tissue specimens are prepared, and in situ hybridization (ISH) is performed to detect the expression of the actin gene (Acta2), and positive signals are counted for each.
- ISH in situ hybridization
- FIG. 41 shows the results of ISH detection of Acta2-expressing cells in tumor specimens.
- A is a representative microscopic image of the Gem group
- B is a typical microscopic image of the Gem + AM80 group
- C is the number of dots of Acta2 positive signal per strongly magnified field of view (400 times) of both groups. It is a figure which compares. There is no difference in the number of dots of the positive signal between the two groups. This result indicates that tamibarotene enhances the effect of the concomitant anticancer drug via mephrin.
- Example 12 Preparation of mephrin overexpressing tumor
- ISH in situ hybridization
- Example 13 Effect of gemcitabine on a tumor overexpressing mephrin
- retinoids other than tamibarotene show similar effects when used in combination with gemcitabine.
- tamibarotene shows similar effects when used in combination with cancer therapeutic agents other than gemcitabine.
- retinoids other than tamibarotene show similar effects when used in combination with anticancer drugs other than gemcitabine.
- Example 14 Functional analysis of mephrin 1
- (1) Experimental method Collect the culture supernatant of the control Flp-In-293 cells or cells stably expressing mouse mephrin (control condition medium, mephrin condition medium). Next, each condition medium is mixed with recombinant human LoxL2 at a specified concentration, and LOX activity is quantified using the LOX activity assay kit (Abcam, ab112139). Since recombinant LOX is inactive, LOXL2 is used.
- Example 15 Functional analysis of mephrin 2
- mice 15-24 weeks old are euthanized and the pancreas is removed to prepare a tissue specimen of the tumor.
- Eight to sixteen images are randomly selected from the tissue specimen of the tumor, the arrangement of collagen is measured with a second harmonic microscope, the coefficient of curvature is calculated, and the linearity of collagen is analyzed.
- FIG. (A) is a representative second harmonic microscopic image of the wild-type KPC group
- (B) is a typical second harmonic microscopic observation image of the mephrin-deficient KPC group
- (C) is a representative second harmonic microscopic image of the collagen of both groups. It is a figure comparing the curvature of curvature, and N in the figure is the number of observation fields. This result indicates that collagen linearity is significantly increased in the mephrin-deficient KPC group.
- Example 16 Effect of tamibarotene on collagen in tumor interstitium
- Tamibarotene (3.0 mg / kg) is orally administered to the AM80 group once daily for 7 days from Day 8.
- DMSO is orally administered to the control group instead of tamibarotene.
- mice are euthanized, tumors are removed, and tissue specimens are prepared. Eight to sixteen images are randomly selected from the tumor tissue specimen, the collagen sequence is measured with a second harmonic microscope, and the curvature (linearity) is analyzed.
- Example 17 Examination of the effect of tamibarotene and gemcitabine depending on the administration time]
- tamibarotene 3.0 mg / kg is orally administered once daily for 10 days from Day 15.
- Gemcitabine 50 mg / kg is administered intraperitoneally once each on Day15, Day18 and Day21.
- DMSO is orally administered on the same day as the pre- and co-administration of tamibarotene. Tumor volume is measured before the start of AM80 administration (Day8), Day12, Day15, Day18, Day21, and Day24. The protocol is shown in FIG.
- Example 18 Effect of tamibarotene, gemcitabine, and immune checkpoint inhibitor combined use
- PDL1 group an anti-PD-L1 antibody-administered group
- PDL1 + AM80 group an anti-PD-L1 antibody and tamibarotene-administered group
- Gemcitabine (100 mg / kg) is administered intraperitoneally on Day7, and 250 ⁇ g / animal of anti-PD-L1 antibody (10F.9G2) is intraperitoneally administered on Day8, Day10, Day12, Day14, Day16 and Day18. Tumor volume is measured every other day from Day1, Day4, Day7 to Day27. The protocol is shown in FIG. In addition, the survival rate until the death of all mice is calculated.
- Example 19 Effect of combined use of tamibarotene and immune checkpoint inhibitor
- mice are subcutaneously transplanted with mouse pancreatic cancer cells mT5 (1.0 x 10 6).
- the tumors are divided into three groups, a control group, an anti-PD-L1 antibody administration group (PDL1 group), and an anti-PD-L1 antibody and tamibarotene administration group (PDL1 + AM80 group) so that the tumor volume becomes even.
- Each group n 7).
- the day of grouping is designated as Day 1
- tamibarotene (3 mg / kg) is orally administered once daily for 7 days from Day 1.
- IgG is administered to the control group instead of the anti-PD-L1 antibody.
- Tumor volume is measured every other day from Day 8 to Day 26. The protocol is shown in FIG. 55. In addition, the survival rate until the death of all mice is calculated.
- Example 20 Effect of tamibarotene and immune checkpoint inhibitor combined use on bladder cancer
- PDL1 group anti-PD-L1 antibody-administered group
- PDL1 + AM80 group anti-PD-L1 antibody and tamibarotene-administered group
- Example 21 Effect of combined use of tamibarotene and immune checkpoint inhibitor on lung cancer
- LCC-luc 1.0 ⁇ 10 6 cells
- luciferase was forcibly expressed in the Lewis lung carcinoma cell line (LCC), which is a mouse lung cancer cell line.
- tamibarotene (3 mg / kg) is orally administered once daily for 7 days.
- Example 22 Effect of combined use of tamibarotene and immune checkpoint inhibitor on gastric cancer
- PDL1 group anti-PD-L1 antibody-administered group
- PDL1 + AM80 group anti-PD-L1 antibody and tamibarotene-administered group
- Tamibarotene is orally administered at 3 mg / kg once daily for 7 days. From the day after the end of tamibarotene administration, 250 ⁇ g / animal of PD-L1 antibody (10F.9G2) is intraperitoneally administered once every 3 days, 3 or 6 times in total. Tumor volume is measured once every 3 days from the start of tamibarotene administration. Compared with the PDL1 group, the PDL1 + AM80 group significantly suppresses tumor growth.
- Example 23 Effect of tamibarotene and immune checkpoint inhibitor combination in mice lacking mephrine]
- PDL1 group an anti-PD-L1 antibody administration group
- PDL1 + AM80 group anti-PD-L1 antibody and tamibarotene administration group
- IgG is administered to the control group instead of the anti-PD-L1 antibody.
- Tumor volume is measured every other day from Day 8 to Day 26. The protocol is shown in FIG. In addition, the survival rate until the death of all mice is calculated.
- Example 24 Effect of combined use of tamibarotene and immune checkpoint inhibitor on gastric cancer
- PD1 group an anti-PD1 antibody-administered group
- PD1 + AM80 group an anti-PD1 antibody and tamibarotene-administered group
- PD1 antibody (10F.9G2) 200 ⁇ g / animal intraperitoneally once every 3 days for a total of 3 times. Tumor volume is measured once every 3 days from the start of tamibarotene administration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
Abstract
Description
[1]レチノイドとがん治療薬との併用療法が有効ながん患者を選択する方法であって、間質中にがん関連線維芽細胞の浸潤を伴う悪性腫瘍を有するがん患者を選択する工程を含む方法。
[2]前記がん患者を選択する工程が、被験がん患者から得られた悪性腫瘍組織において、少なくとも1個のがん関連線維芽細胞を検出することを含む、前記[1]に記載の方法。
[3]前記がん患者を選択する工程が、被験がん患者から得られた悪性腫瘍組織の病理組織標本を作製し、顕微鏡観察下で少なくとも1個のがん関連線維芽細胞を検出することを含む、前記[1]または[2]に記載の方法。
[4]前記がん患者を選択する工程が、被験がん患者から得られた悪性腫瘍組織の病理組織標本を顕微鏡観察し、がん細胞領域と間質領域が含まれる任意の強拡大視野中に1個以上のがん関連線維芽細胞を検出することを含む、前記[1]~[3]のいずれかに記載の方法。
[5]がん関連線維芽細胞の検出が、ヘマトキシリン・エオジン染色を行った病理組織標本を顕微鏡観察することにより行われる、前記[3]または[4]に記載の方法。
[6]がん関連線維芽細胞の検出が、がん関連線維芽細胞のマーカー分子に対する免疫組織化学染色またはin situ hybridizationにより行われる、前記[3]または[4]に記載の方法。
[7]前記[1]~[6]のいずれかに記載の方法により選択されたがん患者を対象とし、レチノイドとがん治療薬とを組み合わせて投与されることを特徴とする医薬。
[8]がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、前記[7]に記載の医薬。
[9]レチノイドがタミバロテンである、前記[7]または[8]に記載の医薬。
[10]レチノイドが先行投与されるように用いられる前記[7]~[9]のいずれかに記載の医薬。
[11]前記[1]~[6]のいずれかに記載の方法により選択されたがん患者を対象とし、レチノイドを有効成分とする、がん治療薬の作用増強用および/またはがん治療薬の標的腫瘍組織への送達促進用医薬。
[12]がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、前記[11]に記載の医薬。
[13]レチノイドがタミバロテンである、前記[11]または[12]に記載の医薬。
[14]前記[1]~[6]のいずれかに記載の方法により選択されたがん患者を対象とし、腫瘍組織の細胞にメフリンを過剰発現させる組成物を有効成分とする、がん治療薬の作用増強用医薬。
[15]メフリンを過剰発現させる組成物がメフリン遺伝子を含有するウイルスベクターである、前記[14]に記載の医薬。
[16]がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、前記[14]または[15]に記載の医薬。
[17]前記[1]~[6]のいずれかに記載の方法により選択されたがん患者を対象とし、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤とがん治療薬とを組み合わせて投与されることを特徴とする医薬。
[18]がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、前記[17]に記載の医薬。
[19]がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤が先行投与されるように用いられる前記[17]または[18]に記載の医薬。
[20]前記[1]~[6]のいずれかに記載の方法により選択されたがん患者を対象とし、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤を有効成分とする、がん治療薬の作用増強用および/またはがん治療薬の標的腫瘍組織への送達促進用医薬。
[21]がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、前記[20]に記載の医薬。
本発明は、レチノイドとがん治療薬とを組み合わせて投与されるがん治療用医薬を提供する(以下、「本発明の第1の医薬」と記す)。本発明の第1の医薬の投与対象は、間質中にがん関連線維芽細胞の浸潤を伴う悪性腫瘍を有するがん患者である。間質中にがん関連線維芽細胞の浸潤を伴う悪性腫瘍を有するがん患者は、以下で説明する方法により選択することができる。このようなレチノイドとがん治療薬との併用療法が有効ながん患者を選択する方法も、本発明に含まれる。
本発明は、腫瘍組織の細胞にメフリンを過剰発現させる組成物を有効成分とする、がん治療薬の作用増強用医薬を提供する(以下、「本発明の第2の医薬」と記す)。本発明の第2の医薬の投与対象は、本発明の第1の医薬の投与対象と同じ、間質中にCAFの浸潤を伴う悪性腫瘍を有するがん患者である。したがって、本発明の第2の医薬の投与対象は、上述の本発明のがん患者選択方法によって選択することができる。
本発明は、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤とがん治療薬とを組み合わせて投与されるがん治療用医薬を提供する(以下、「本発明の第3の医薬」と記す)。本発明の第3の医薬の投与対象は、本発明の第1の医薬の投与対象と同じ、間質中にCAFの浸潤を伴う悪性腫瘍を有するがん患者である。したがって、本発明の第3の医薬の投与対象は、上述の本発明のがん患者選択方法によって選択することができる。
(1)上記本発明のがん患者選択方法により選択されたがん患者に、レチノイドとがん治療薬とを組み合わせて投与することを含む、がん治療方法。
(2)上記本発明のがん患者選択方法により選択されたがん患者に、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤とがん治療薬とを組み合わせて投与することを含む、がん治療方法。
(3)上記本発明のがん患者選択方法により選択され、がん治療薬を投与されている患者に、レチノイド、腫瘍組織の細胞にメフリンを過剰発現させる組成物、または、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤を投与することを含む、がん治療薬の作用増強方法。
(4)上記本発明のがん患者選択方法により選択され、がん治療薬を投与されている患者に、レチノイド、または、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤を投与することを含む、がん治療薬の標的腫瘍組織への送達促進方法。
(5)がん治療用医薬を製造するための、レチノイド、または、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤の使用であって、上記本発明のがん患者選択方法により選択され、がん治療薬を投与されている患者を対象とする使用。
(6)がん治療薬の作用増強用医薬を製造するための、レチノイド、腫瘍組織の細胞にメフリンを過剰発現させる組成物、または、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤の使用であって、上記本発明のがん患者選択方法により選択され、がん治療薬を投与されている患者を対象とする使用。
(7)がん治療薬の標的腫瘍組織への送達促進用医薬を製造するための、レチノイド、または、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤の使用であって、上記本発明のがん患者選択方法により選択され、がん治療薬を投与されている患者を対象とする使用。
(8)レチノイドおよびがん治療薬を含むがん治療キットであって、レチノイドとがん治療薬が別の容器に入っており、上記本発明のがん患者選択方法により選択されたがん患者を治療対象とする、キット。
(9)上記本発明のがん患者選択方法により選択され、がん治療薬を投与されている患者のがん治療に使用するための、レチノイド。
(10)上記本発明のがん患者選択方法により選択され、がん治療薬を投与されている患者のがん治療に使用するための、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤。
(11)上記本発明のがん患者選択方法により選択され、がん治療薬を投与されている患者におけるがん治療薬の作用増強のための、レチノイド、腫瘍組織の細胞にメフリンを過剰発現させる組成物、または、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤の使用。
(12)上記本発明のがん患者選択方法により選択され、がん治療薬を投与されている患者におけるがん治療薬の標的腫瘍組織への送達を促進するための、レチノイド、または、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤の使用。
手術または生検で得られる腫瘍組織から、定法に従って組織標本を作製し、HE染色を行う。病理診断医がHE染色標本を顕微鏡で観察し、形態学的にCAFの有無を判定する。
手術または生検で得られた腫瘍組織から作製した組織標本に対して、CAFのマーカー分子に対する抗体を用いるIHCまたはCAFのマーカー分子のmRNAにハイブリダイズするプローブを用いるISHを行い、顕微鏡で観察して陽性シグナルの有無により判定する。本実施例では、CAFのマーカー分子としてメフリンを採用し、抗メフリン抗体を用いるIHCとメフリン遺伝子のmRNAにハイブリダイズするプローブを用いるISHを行う。
(1)実験方法
BALB/c-nu雌性ヌードマウスにヒトすい臓がん細胞BxPC-3(1.0×106個)を皮下移植し、がん細胞単独移植群とする。また、BALB/c-nu雌性ヌードマウスにヒトすい臓がん細胞BxPC-3(1.0×106個)とヒト膵星細胞(5.0×106個)を皮下移植し、共移植群とする。膵星細胞は膵臓の線維芽細胞であり、CAFの起源細胞と考えられている。がん細胞単独移植群および共移植群をそれぞれゲムシタビン(Gem)とタミバロテン(AM80)を投与する群(Gem+AM80群)およびGemとDMSOを投与する群(Gem+DMSO群)の2群に分ける。AM80(3.0mg/kg)またはDMSOは移植後3日目より14日目まで連日経口投与する。Gem(50mg/kg)は移植後6日目より3日に1回腹腔内投与する。移植後15日目に腫瘍体積を測定する。プロトコールを図25に示す。
結果を図26に示す。(A)はがん細胞単独移植群の結果、(B)は共移植群の結果である。がん細胞単独移植群では、Gem+AM80群とGem+DMSO群との間に有意差は認められない。共移植群では、Gem+AM80群で有意に縮小効果が得られる。この結果は、間質中にCAFの浸潤を伴う悪性腫瘍では抗がん剤の腫瘍縮小効果をAM80が増強することを示す。
(1)実験方法
初代ヒト膵星細胞は、東北大学・正宗博士から分与を受けたものを使用する。初代マウス間葉系幹細胞はCyagen株式会社より購入したものを使用する。膵星細胞および間葉系幹細胞は、どちらもCAFの起源細胞と考えられている。レチノイドは、SCREEN-WELL Nuclear Receptor ligand library(ENZO)に含まれるレチノイドを使用する。培養液は、DMEM+10%FBSを使用する。コラーゲンコートディッシュに細胞を播種して100%コンフルエントになるまで培養し、各種レチノイドを濃度が1μMとなるように添加する。48時間後に細胞を回収し、RNeasyPLUS KIT(QIAGEN)を使用しRNAを抽出し、ReverseTra Ace qPCR RT Master Mix(TOYOBO)を使用してcDNAを合成する。Gene expression assay(Thermo Fisher scientific)を使用して、qPCRでメフリン遺伝子(ISLRおよびIslr)の発現量を測定する。
初代ヒト膵星細胞の結果を表1に示す。ISLR発現量は、コントロール(DMSO処理細胞)のISLR発現量を1としたときの相対発現量で示している。用いたレチノイドは、すべてISLR発現量を上昇させる。ここで、がん促進性CAFのマーカーはαSMA(遺伝子名:ACTA2)であり、がん抑制性CAFのマーカーはメフリン(遺伝子名:ISLR)であり、CAFにおける両マーカーの発現量は反比例することがわかっている。したがって、この結果はレチノイドがヒトのがん促進性CAFをがん抑制性CAFにリプログラミングすることを示す。
(1)実験方法
実施例4の初代マウス間葉系幹細胞を用いた実験と同じ方法で行う。レチノイドとしてATRA、AM80およびAM580を用いる。メフリン遺伝子(Islr)、アクチン遺伝子(Acta2)、I型コラーゲン遺伝子(Col1a1)およびIII型コラーゲン遺伝子(Col3a1)の発現量をqPCRで測定する。
結果を図27に示す。(A)がメフリン遺伝子(Islr)、(B)がアクチン遺伝子(Acta2)、(C)がI型コラーゲン遺伝子(Col1a1)、(D)がIII型コラーゲン遺伝子(Col3a1)の結果である。コントロール(DMSO)では、Acta2、Col1a1およびCol3a1の発現量が高く、Islrの発現量が低い。一方レチノイド(ATRA、AM80、AM580)処理群は、Islrが高くなり、Acta2、Col1a1およびCol3a1の発現量が低くなる。この結果は、がん促進性CAFが、レチノイドによりがん抑制性CAFにリプログラミングされることを示す。
(1)実験方法
コールド・スプリング・ハーバー研究所のDavid Tuveson博士から分与を受けた、すい臓がん細胞mT5を使用する。mT5は、すい臓がん自然発症モデルであるKPCマウスに発症したすい腫瘍から樹立したすい臓がん細胞である(Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31.)。
(2-1)腫瘍体積
腫瘍体積の推移を図29に示す。各群間に有意差はなく、いずれの濃度のAM80を投与しても、すい臓がん細胞の増殖を抑制しない。また、AM80の投与はマウスの体重に影響を及ぼさない。
腫瘍標本におけるIslrの発現をISHで検出した結果を図30に示す。(A)はコントロール群の代表的な顕微鏡観察像、(B)はAM80の3 mg/kg/day群の代表的な顕微鏡観察像、(C)はコントロール群およびAM80の3 mg/kg/day群における強拡大視野(400倍)あたりのIslr陽性シグナルのドット数を比較する図である。AM80投与により、抑制性CAFのマーカーであるIslrの発現は上昇しており、AM80の3 mg/kg/day群のIslr陽性シグナルのドット数は、コントロール群より有意に多い。
腫瘍標本におけるActa2の発現細胞をISHで検出した結果を図31に示す。(A)はコントロール群の代表的な顕微鏡観察像、(B)はAM80の3 mg/kg/day群の代表的な顕微鏡観察像、(C)はコントロール群およびAM80の3 mg/kg/day群における強拡大視野(400倍)あたりのActa2陽性シグナルのドット数を比較する図である。AM80投与により、促進性CAFのマーカーであるActa2の発現は減少しており、AM80の3 mg/kg/day群のActa2陽性シグナルのドット数は、コントロール群より有意に少ない。
腫瘍標本を抗CD31抗体で免疫染色した結果を図32に示す。(A)はコントロール群の代表的な顕微鏡観察像、(B)はAM80の3 mg/kg/day群の代表的な顕微鏡観察像、(C)はコントロール群とAM80の3 mg/kg/day群の血管内腔面積を比較する図である。AM80の3 mg/kg/day群の血管内腔面積は、コントロール群の血管内腔面積より有意に増加している。
C57BL/6J雌性マウスの皮下にマウスすい臓がん細胞mT5を移植して形成された腫瘍は、CAFマーカーであるIslrまたはActa2が発現していることから、間質中にCAFの浸潤を伴う悪性腫瘍と判定される。実施例6の結果は、がん促進性CAFがある状態(コントロール群、Acta2陽性)では間質内圧が高く血管は圧により押しつぶされていると考えられ、AM80投与によりがん抑制性CAFにリプログラミングされると(Islr陽性)、コラーゲン産生等が変化して間質のリモデリングが起こり、間質内圧が低下して押しつぶされていた血管が開くと考えられる。これにより、腫瘍へのドラッグデリバリーが改善されると考えられる。
(1)実験方法
C57BL/6J雌性マウスに、マウスすい臓がん細胞mT5(1.0×106個)を皮下移植する。8日後(Day8)に、腫瘍体積が均等になるようにコントロール群、ゲムシタビン投与群(Gem群)およびゲムシタビンとタミバロテン投与群(Gem+AM80群)の3群に群分けする(各群n=8)。Gem+AM80群には、Day8から1日1回17日間、タミバロテン(3.0mg/kg)を経口投与する。また、Gem群およびGem+AM80群には、ゲムシタビン(50mg/kg)をDay15、Day18およびDay21に各1回ずつ腹腔内投与する。コントロール群には、タミバロテンの代わりにDMSOを経口投与し、ゲムシタビンの代わりに生理食塩水を腹腔内投与する。AM80投与開始前(Day8)、Day12、Day15、Day18、Day21、Day24に腫瘍体積を測定する。プロトコールを図33に示す。
結果を図34に示す。図34は、Gem群はコントロール群より有意に腫瘍増殖を抑制し、Gem+AM80群はGem群より有意に腫瘍増殖を抑制することを示す。この結果は、タミバロテンがゲムシタビンの腫瘍増殖抑制作用を顕著に増強することを示す。
(1)実験方法
BALB/c-nu雌性ヌードマウスに、ヒトすい臓がん細胞BxPC-3(1.0×106個)を皮下移植する。腫瘍体積が50~150 mm3に達した時点で、腫瘍体積が均等になるようにコントロール群、ゲムシタビンとナブパクリタキセル投与群(Gem+nabPTX群)、およびゲムシタビンとナブパクリタキセルとタミバロテン投与群(Gem+nabPTX+AM80群)の3群に群分けする(各群n=7)。Gem+nabPTX+AM80群には、群分け日(Day1)から1日1回17日間、タミバロテン(3.0mg/kg)を経口投与する。また、Gem+nabPTX群およびGem+nabPTX+AM80群には、ゲムシタビン(50mg/kg)をDay7、Day10およびDay13に各1回ずつ腹腔内投与し、ナブパクリタキセル(5mg/kg)をDay7、Day10およびDay13に各1回ずつ静脈内投与する。コントロール群には、タミバロテンの代わりにDMSOを経口投与し、ゲムシタビンの代わりに生理食塩水を腹腔内投与し、ナブパクリタキセルの代わりに生理食塩水を静脈内投与する。AM80投与開始前(Day1)、Day4、Day7、Day10、Day13、Day16に腫瘍体積を測定する。プロトコールを図35に示す。
結果を図36に示す。図36は、Gem+nabPTX群はコントロール群より有意に腫瘍増殖を抑制し、Gem+nabPTX+AM80群はGem+nabPTX群より有意に腫瘍増殖を抑制することを示す。この結果は、タミバロテンがゲムシタビンとナブパクリタキセル併用の腫瘍増殖抑制作用を、さらに顕著に増強することを示す。
(1)実験方法
マウスすい臓がん自然発症モデル(KPCマウス)(S. R. Hingorani et al., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).)において腹部エコー検査で膵腫瘍長径が1mm以上になったことを確認した時点(Day1)から、1日1回17日間、タミバロテン(3.0mg/kg)を経口投与する。ゲムシタビンとタミバロテン投与群(Gem+AM80群、n=5)には、ゲムシタビン(50mg/kg)をDay7、Day10およびDay13に各1回ずつ腹腔内投与する。コントロール群(Gem群、n=5)には、ゲムシタビン(50mg/kg)をDay7、Day10およびDay13に各1回ずつ腹腔内投与するが、タミバロテンは投与しない。AM80投与開始前(Day1)、Day8、Day15、Day22に腫瘍長径を測定する。プロトコールを図37に示す。
結果を図38に示す。図38は、Gem+AM80群はコントロール群(Gem群)より有意に腫瘍増殖を抑制することを示す。KPCマウスはCAFの浸潤を伴うより多くの豊富な間質を有しておりヒト膵腫瘍に最も近いマウスモデルである。この自然発症モデルにおいてもタミバロテンがゲムシタビンの腫瘍増殖抑制作用を顕著に増強することを示す。
(1)実験方法
ゲムシタビンに代えて抗PD1抗体または抗PDL1抗体を用いる以外は、実施例9と同じ方法で実験を行う。その結果、タミバロテンと抗PD1抗体または抗PDL1抗体との併用群はコントロール群(抗PD1抗体単独投与群または抗PDL1抗体単独投与群)より有意に腫瘍増殖を抑制する。
(1)実験方法
メフリン欠失マウス(Maeda K. et al., Sci Rep. 2016 Feb 29;6:22288. doi: 10.1038/srep22288.)に、マウスすい臓がん細胞mT5(1.0×106個)を皮下移植する。8日後(Day8)に、腫瘍体積が均等になるようにゲムシタビン単独投与群(Gem群、n=6)、ゲムシタビンとタミバロテン投与群(Gem+AM80群、n=6)の2群に群分けする。Gem+AM80群にはDay8から1日1回17日間、タミバロテン(3.0mg/kg)を経口投与する。Gem群およびGem+AM80群には、ゲムシタビン(50mg/kg)をDay15、Day18およびDay21に各1回ずつ腹腔内投与する。AM80投与開始前(Day8)、Day12、Day15、Day18、Day21、Day24に体重と腫瘍体積を測定する。Day24にマウスを安楽死させて腫瘍を摘出し組織標本を作製して、アクチン遺伝子(Acta2)の発現を検出するためにin situ hybridization(ISH)を行い、それぞれ陽性シグナルをカウントする。プロトコールを図39に示す。
(2-1)腫瘍体積
腫瘍体積の推移を図40に示す。両群間に有意差はなく、ゲムシタビンとタミバロテンの併用は、メフリン欠失マウスに移植されたすい臓がん細胞の増殖を抑制しない。両群間の体重にも有意差はない。
腫瘍標本におけるActa2の発現細胞をISHで検出した結果を図41に示す。(A)はGem群の代表的な顕微鏡観察像、(B)はGem+AM80群の代表的な顕微鏡観察像、(C)は両群の強拡大視野(400倍)あたりのActa2陽性シグナルのドット数を比較する図である。両群の陽性シグナルのドット数に差は認められない。この結果は、タミバロテンはメフリンを介して併用抗がん薬の効果を増強することを示す。
(1)実験方法
C57BL/6J雌性マウスに、マウスすい臓がん細胞mT5(1.0×106個)を皮下移植する。腫瘍体積が50~100 mm3に達した時点で、腫瘍体積が均等になるように2群に分ける(各群n=7)。群分け日(Day1)、Day5およびDay9に、感染細胞にメフリンを過剰発現させるセンダイウイルス(SeV-Meflin)、および、感染細胞にGFPを過剰発現させるセンダイウイルス(SeV-GFP)をそれぞれ腫瘍内投与する。Day17に腫瘍体積を測定した後、マウスを安楽死させて腫瘍を摘出して組織標本を作製し、メフリン遺伝子(Islr)の発現を検出するためにin situ hybridization(ISH)を行う。プロトコールを図42に示す。
ISHの結果を図43に示す。(A)SeV-GFP群の代表的な顕微鏡観察像であり、(B)はSeV-Meflin群の代表的な顕微鏡観察像である。SeV-Meflin群ではメフリンが過剰発現している。腫瘍体積の推移を図44に示す。両群間に有意差はない。
(1)実験方法
C57BL/6J雌性マウスに、マウスすい臓がん細胞mT5(1.0×106個)を皮下移植する。腫瘍体積が50~100 mm3に達した時点で、腫瘍体積が均等になるように2群に分ける(各群n=8)。群分け日(Day1)、Day5およびDay9に、感染細胞にメフリンを過剰発現させるセンダイウイルス(SeV-Meflin)、感染細胞にGFPを過剰発現させるセンダイウイルス(SeV-GFP)をそれぞれ腫瘍内投与する。また、ゲムシタビン(50mg/kg)をDay5、Day8、Day11およびDay14に各1回ずつ腹腔内投与する。Day17に腫瘍体積を測定する。プロトコールを図45に示す。
結果を図46に示す。SeV-Meflin群にゲムシタビンを投与すると、SeV-GFP群にゲムシタビンを投与するより有意に腫瘍増殖を抑制する。この結果は、腫瘍にメフリン遺伝子を導入してメフリンを過剰発現させることにより、抗がん剤の効果が増強されることを示す。
(1)実験方法
コントロールのFlp-In-293細胞またはマウスメフリンを安定して発現している細胞の培養上清を回収する(コントロールコンディション培地、メフリンコンディション培地)。次に、各コンディション培地を指定の濃度で組換えヒトLoxL2と混合し、LOX activity assay kit(Abcam社, ab112139)を用いてLOX活性を定量する。なお、組換えLOXは活性がないためLOXL2を使用する。
結果を図47に示す。この結果は、メフリンが有意にLOX活性を阻害することを示す。
(1)実験方法
マウスすい臓がん自然発症モデルであるKPCマウス(野生型)とメフリン欠失KPCマウス(Maeda K, et al. Identification of Meflin as a potential marker for mesenchymal stromal cells. Sci Rep 2016;6:22288.)を使用する(各群n=6)。腫瘍による死亡直前のマウス(15~24週齢)を安楽死させてすい臓を摘出し、腫瘍の組織標本を作製する。腫瘍の組織標本からランダムに8~16枚の画像を選択し、第二高調波顕微鏡でコラーゲンの配列を測定し、曲率係数(coefficient of curvature)を算出してコラーゲンの直線性を解析する。
結果を図48に示す。(A)は野生型KPC群の代表的な第二高調波顕微鏡観察像、(B)はメフリン欠失KPC群の代表的な第二高調波顕微鏡観察像、(C)は両群のコラーゲンの曲率係数(coefficient of curvature)を比較した図であり、図中Nは観察視野数である。この結果はメフリン欠失KPC群において有意にコラーゲンの直線性が増加することを示す。
(1)実験方法
C57BL/6J雌性マウスに、マウスすい臓がん細胞mT5(1.0×106個)を皮下移植する。8日後(Day8)に、腫瘍体積が均等になるように、コントロール群およびタミバロテン投与群(AM80群)の2群に群分けする(各群n=5)。AM80群にはDay8から1日1回7日間、タミバロテン(3.0mg/kg)を経口投与する。コントロール群には、タミバロテンの代わりにDMSOを経口投与する。Day15にマウスを安楽死させて腫瘍を摘出し、組織標本を作製する。腫瘍の組織標本からランダムに8~16枚の画像を選択し、第二高調波顕微鏡でコラーゲンの配列を測定し、曲率(直線性)を解析する。
結果を図49に示す。(A)はコントロール群の代表的な第二高調波顕微鏡観察像、(B)はAM80群の代表的な第二高調波顕微鏡観察像、(C)は両群のコラーゲンの曲率(直線性)を比較した図である。この結果は、コントロール群において有意にコラーゲンの直線性が増加することを示す。この結果から、AM80群ではタミバロテンの投与によりCAFのメフリン発現が誘導されて間質のLOXの活性を阻害することで、コラーゲンの直線性が低下することが示唆される。
(1)実験方法
C57BL/6J雌性マウスに、マウスすい臓がん細胞mT5(1.0×106個)を皮下移植する。8日後(Day8)に、腫瘍体積が均等になるように、ゲムシタビン単独投与群(Gem群)、タミバロテン事前投与+ゲムシタビン投与群(AM80事前+Gem群)およびタミバロテン事前・同時投与+ゲムシタビン投与群(AM80事前&同時+Gem群)の3群に群分けする(各群n=5)。タミバロテン事前投与はDay8から1日1回7日間タミバロテン(3.0mg/kg)を経口投与する。タミバロテン同時投与はDay15から1日1回10日間タミバロテン(3.0mg/kg)を経口投与する。ゲムシタビン(50mg/kg)はDay15、Day18およびDay21に各1回ずつ腹腔内投与する。タミバロテン非投与マウス(Gem群)にはタミバロテンの事前・同時投与と同日にDMSOを経口投与する。AM80投与開始前(Day8)、Day12、Day15、Day18、Day21、Day24に腫瘍体積を測定する。プロトコールを図50に示す。
腫瘍体積の推移を図51に示す。この結果は、AM80事前+Gem群は、AM80事前&同時+Gem群と同程度に腫瘍増殖を抑制することを示す。
(1)実験方法
C57BL/6J雌性マウスに、マウスすい臓がん細胞mT5(1.0×106個)を皮下移植する。移植後8日目に腫瘍体積が均等になるように、抗PD-L1抗体投与群(PDL1群)および抗PD-L1抗体とタミバロテン投与群(PDL1+AM80群)の2群に群分けする(各群n=7)。群分けした日をDay1とし、Day1から1日1回7日間タミバロテン(3 mg/kg)を経口投与する。Day7にゲムシタビン(100mg/kg)、Day8、Day10、Day12、Day14、Day16およびDay18に抗PD-L1抗体(10F.9G2)250 μg/匹を腹腔内投与する。Day1、Day4、Day7からDay27まで1日おきに腫瘍体積を測定する。プロトコールを図52に示す。さらに、全部のマウスが死亡するまでの生存率を求める。
腫瘍体積の推移を図53に示す。この結果は、PDL1群と比較してPDL1+AM80群は有意に腫瘍増殖を抑制することを示す。生存率の推移を図54に示す。この結果は、PDL1群と比較してPDL1+AM80群では有意な生存の延長が認められることを示す。
(1)実験方法
C57BL/6J雌性マウスに、マウスすい臓がん細胞mT5(1.0×106個)を皮下移植する。移植後8日目に腫瘍体積が均等になるように、コントロール群、抗PD-L1抗体投与群(PDL1群)および抗PD-L1抗体とタミバロテン投与群(PDL1+AM80群)の3群に群分けする(各群n=7)。群分けした日をDay1とし、Day1から1日1回7日間タミバロテン(3 mg/kg)を経口投与する。Day8、Day10、Day12、Day14、Day16およびDay18に抗PD-L1抗体(10F.9G2)250 μg/匹を腹腔内投与する。コントロール群には抗PD-L1抗体に代えてIgGを投与する。Day8からDay26まで1日おきに腫瘍体積を測定する。プロトコールを図55に示す。さらに、全部のマウスが死亡するまでの生存率を求める。
腫瘍体積の推移を図56に示す。この結果は、PDL1群と比較してPDL1+AM80群は有意に腫瘍増殖を抑制することを示す。生存率の推移を図57に示す。この結果は、PDL1群と比較してPDL1+AM80群では有意な生存の延長が認められることを示す。
(1)実験方法
C57BL/6J雌性マウスに、マウス膀胱がん細胞MB49(1.0×106個)を皮下移植する(Day1)。Day5に腫瘍体積が均等になるように、抗PD-L1抗体投与群(PDL1群)および抗PD-L1抗体とタミバロテン投与群(PDL1+AM80群)の2群に群分けする(各群n=5)。Day5から1日1回7日間タミバロテン(3 mg/kg)を経口投与する。Day12、Day15、Day18およびDay21に抗PD-L1抗体(10F.9G2)250 μg/匹 を腹腔内投与する。Day2からDay40まで3日に1回腫瘍体積を測定する。プロトコールを図58に示す。
腫瘍体積の推移を図59に示す。この結果は、PDL1群と比較してPDL1+AM80群は有意に腫瘍増殖を抑制することを示す。
(1)実験方法
C57BL/6J雌性マウスに、マウス肺がん細胞株であるLewis lung carcinoma cell line(LCC)にルシフェラーゼ (Luciferase)を強制発現させた細胞LCC-luc(1.0×106個)を皮下移植する(Day1)。Day5に腫瘍体積が均等になるように、抗PD-L1抗体投与群(PDL1群)および抗PD-L1抗体とタミバロテン投与群(PDL1+AM80群)の2群に群分けする(各群n=5)。Day9から1日1回7日間タミバロテン(3 mg/kg)を経口投与する。Day16、Day19およびDay22に抗PD-L1抗体(10F.9G2)250 μg/匹 を腹腔内投与する。Day9からDay40まで3日に1回腫瘍体積を測定する。
腫瘍体積の推移を図60に示す。この結果は、PDL1群と比較してPDL1+AM80群は有意に腫瘍増殖を抑制することを示す。
(1)実験方法
C57BL/6J雌性マウスに、マウス胃がん細胞株YTN5またはYTN16(1.0~5.0×106個)を皮下移植する(Day1)。Day5に腫瘍体積が均等になるように、抗PD-L1抗体投与群(PDL1群)および抗PD-L1抗体とタミバロテン投与群(PDL1+AM80群)の2群に群分けする(各群n=5)。Day5-9のいずれかにタミバロテンの投与を開始する。タミバロテンは1日1回7日間、3 mg/kgを経口投与する。タミバロテンの投与終了翌日から3日に1回、合計3回または6回PD-L1抗体(10F.9G2)250 μg/匹を腹腔内投与する。タミバロテンの投与開始から3日に1回腫瘍体積を測定する。PDL1群と比較してPDL1+AM80群は有意に腫瘍増殖を抑制する。
(1)実験方法
メフリン欠失マウス(Maeda K. et al., Sci Rep. 2016 Feb 29;6:22288. doi: 10.1038/srep22288.)に、マウスすい臓がん細胞mT5(1.0×106個)を皮下移植する。移植後8日目に腫瘍体積が均等になるように、コントロール群、抗PD-L1抗体投与群(PDL1群)および抗PD-L1抗体とタミバロテン投与群(PDL1+AM80群)の3群に群分けする(各群n=7)。群分けした日をDay1とし、Day1から1日1回7日間タミバロテン(3 mg/kg)を経口投与する。Day8、Day10、Day12、Day14、Day16およびDay18に抗PD-L1抗体(10F.9G2)250 μg/匹を腹腔内投与する。コントロール群には抗PD-L1抗体に代えてIgGを投与する。 Day8からDay26まで1日おきに腫瘍体積を測定する。プロトコールを図61に示す。さらに、全部のマウスが死亡するまでの生存率を求める。
腫瘍体積の推移を図62に示す。この結果は、腫瘍増殖を抑制効果に関し、PDL1群とPDL1+AM80群との間に有意差は認められないことを示す。生存率の推移を図63に示す。この結果は、生存率に関し、PDL1群とPDL1+AM80群との間に有意差は認められないことを示す。
(1)実験方法
C57BL/6J雌性マウスに、マウス胃がん細胞株YTN5(5.0×106個)を皮下移植する(Day1)。Day7に腫瘍体積が均等になるように、抗PD1抗体投与群(PD1群)および抗PD1抗体とタミバロテン投与群(PD1+AM80群)の2群に群分けする(各群n=6)。Day7にタミバロテンの投与を開始する。タミバロテンは1日1回6日間、3 mg/kgを経口投与する。タミバロテンの投与終了翌日から3日に1回、合計3回PD1抗体(10F.9G2)200 μg/匹を腹腔内投与する。タミバロテンの投与開始から3日に1回腫瘍体積を測定する。
腫瘍体積の推移を図64に示す。この結果は、PD1群と比較してPD1+AM80群は有意に腫瘍増殖を抑制することを示す。
Claims (21)
- レチノイドとがん治療薬との併用療法が有効ながん患者を選択する方法であって、間質中にがん関連線維芽細胞の浸潤を伴う悪性腫瘍を有するがん患者を選択する工程を含む方法。
- 前記がん患者を選択する工程が、被験がん患者から得られた悪性腫瘍組織において、少なくとも1個のがん関連線維芽細胞を検出することを含む、請求項1に記載の方法。
- 前記がん患者を選択する工程が、被験がん患者から得られた悪性腫瘍組織の病理組織標本を作製し、顕微鏡観察下で少なくとも1個のがん関連線維芽細胞を検出することを含む、請求項1または2に記載の方法。
- 前記がん患者を選択する工程が、被験がん患者から得られた悪性腫瘍組織の病理組織標本を顕微鏡観察し、がん細胞領域と間質領域が含まれる任意の強拡大視野中に1個以上のがん関連線維芽細胞を検出することを含む、請求項1~3のいずれかに記載の方法。
- がん関連線維芽細胞の検出が、ヘマトキシリン・エオジン染色を行った病理組織標本を顕微鏡観察することにより行われる、請求項3または4に記載の方法。
- がん関連線維芽細胞の検出が、がん関連線維芽細胞のマーカー分子に対する免疫組織化学染色またはin situ hybridizationにより行われる、請求項3または4に記載の方法。
- 請求項1~6のいずれかに記載の方法により選択されたがん患者を対象とし、レチノイドとがん治療薬とを組み合わせて投与されることを特徴とする医薬。
- がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、請求項7に記載の医薬。
- レチノイドがタミバロテンである、請求項7または8に記載の医薬。
- レチノイドが先行投与されるように用いられる請求項7~9のいずれかに記載の医薬。
- 請求項1~6のいずれかに記載の方法により選択されたがん患者を対象とし、レチノイドを有効成分とする、がん治療薬の作用増強用および/またはがん治療薬の標的腫瘍組織への送達促進用医薬。
- がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、請求項11に記載の医薬。
- レチノイドがタミバロテンである、請求項11または12に記載の医薬。
- 請求項1~6のいずれかに記載の方法により選択されたがん患者を対象とし、腫瘍組織の細胞にメフリンを過剰発現させる組成物を有効成分とする、がん治療薬の作用増強用医薬。
- メフリンを過剰発現させる組成物がメフリン遺伝子を含有するウイルスベクターである、請求項14に記載の医薬。
- がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、請求項14または15に記載の医薬。
- 請求項1~6のいずれかに記載の方法により選択されたがん患者を対象とし、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤とがん治療薬とを組み合わせて投与されることを特徴とする医薬。
- がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、請求項17に記載の医薬。
- がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤が先行投与されるように用いられる請求項17または18に記載の医薬。
- 請求項1~6のいずれかに記載の方法により選択されたがん患者を対象とし、がんの間質におけるリシルオキシダーゼの活性抑制を誘導する薬剤を有効成分とする、がん治療薬の作用増強用および/またはがん治療薬の標的腫瘍組織への送達促進用医薬。
- がん治療薬が化学療法剤、分子標的薬、免疫療法剤またはホルモン療法剤である、請求項20に記載の医薬。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21830069.7A EP4173639A4 (en) | 2020-06-26 | 2021-06-28 | METHOD FOR SELECTING A CANCER PATIENT WITH EFFECT OF COMBINATION THERAPY WITH RETINOID AND CANCER TREATMENT |
CN202180045356.5A CN115997122A (zh) | 2020-06-26 | 2021-06-28 | 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物 |
JP2022532558A JP7327855B2 (ja) | 2020-06-26 | 2021-06-28 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
KR1020237000437A KR20230031285A (ko) | 2020-06-26 | 2021-06-28 | 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약 |
CA3184767A CA3184767A1 (en) | 2020-06-26 | 2021-06-28 | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
US18/010,686 US20230301950A1 (en) | 2020-06-26 | 2021-06-28 | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-110560 | 2020-06-26 | ||
JP2020110560 | 2020-06-26 | ||
JP2021078852 | 2021-05-06 | ||
JP2021-078852 | 2021-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021261601A1 true WO2021261601A1 (ja) | 2021-12-30 |
Family
ID=79281455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/024382 WO2021261601A1 (ja) | 2020-06-26 | 2021-06-28 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230301950A1 (ja) |
EP (1) | EP4173639A4 (ja) |
JP (1) | JP7327855B2 (ja) |
KR (1) | KR20230031285A (ja) |
CN (1) | CN115997122A (ja) |
CA (1) | CA3184767A1 (ja) |
TW (1) | TW202216133A (ja) |
WO (1) | WO2021261601A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023210634A1 (ja) * | 2022-04-28 | 2023-11-02 | 国立大学法人東海国立大学機構 | 拡張障害を伴う心不全の治療用医薬組成物 |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US20040248871A1 (en) | 2001-08-03 | 2004-12-09 | Jean Farjanel | Use of lysyl oxidase inhibitors for cell culture and tissue engineering |
WO2005007828A2 (en) | 2003-07-14 | 2005-01-27 | Prolx Pharmaceuticals, Inc. | Regulation of hif protein levels via deubiquitination pathways |
WO2006026430A2 (en) | 2004-08-27 | 2006-03-09 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogues and methods of use thereof |
WO2006028958A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
WO2007131201A2 (en) | 2006-05-05 | 2007-11-15 | Irm Llc | Compounds and compositions as hedgehog pathway modulators |
WO2008009437A2 (en) | 2006-07-18 | 2008-01-24 | Noxxon Pharma Ag | Sdf-i binding nucleic acids |
US20090005416A1 (en) | 2007-06-29 | 2009-01-01 | Pfizer Inc. | Benzimidazole derivatives |
WO2009017833A2 (en) | 2007-08-02 | 2009-02-05 | Arresto Biosciences | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
WO2009019007A2 (en) | 2007-08-06 | 2009-02-12 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof |
WO2009107850A2 (en) | 2008-02-26 | 2009-09-03 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
WO2010147917A1 (en) | 2009-06-19 | 2010-12-23 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
WO2011097513A1 (en) | 2010-02-04 | 2011-08-11 | Gilead Biologics, Inc | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
WO2012012300A2 (en) | 2010-07-20 | 2012-01-26 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
WO2012031773A1 (en) | 2010-09-09 | 2012-03-15 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
WO2012049277A1 (en) | 2010-10-14 | 2012-04-19 | Proximagen Ltd | Cxcr4 receptor antagonists |
WO2013048164A1 (en) | 2011-09-27 | 2013-04-04 | Dongguk University Industry-Academic Cooperation Foundation | NOVEL COMPOUNDS AS HIF-1αINHIBITORS AND MANUFACTURING PROCESS THEREOF |
WO2014001464A1 (en) | 2012-06-27 | 2014-01-03 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
WO2015035223A1 (en) | 2013-09-09 | 2015-03-12 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
WO2015178426A1 (ja) * | 2014-05-21 | 2015-11-26 | 国立研究開発法人産業技術総合研究所 | がん幹細胞の増殖抑制剤 |
WO2016144703A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
WO2016157149A1 (en) | 2015-04-02 | 2016-10-06 | Proximagen Limited | Novel therapies for cancer |
JP2017048225A (ja) * | 2007-03-30 | 2017-03-09 | 日東電工株式会社 | がん細胞および癌随伴線維芽細胞への標的化剤 |
WO2017136871A1 (en) | 2016-02-12 | 2017-08-17 | Pharmaxis Ltd. | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof |
WO2018011376A1 (en) | 2016-07-13 | 2018-01-18 | Centre National De La Recherche Scientifique - Cnrs - | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines |
US20180201640A1 (en) | 2017-01-13 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | 4-methylumbelliferone derivatives for treatment for immune modulation |
WO2018157190A1 (en) | 2017-03-02 | 2018-09-07 | Pharmaxis Ltd. | Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof |
WO2020024017A1 (en) | 2018-08-03 | 2020-02-06 | Pharmaxis Ltd. | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof |
WO2021012014A1 (en) | 2019-07-25 | 2021-01-28 | Pharmaxis Ltd. | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof |
-
2021
- 2021-06-28 US US18/010,686 patent/US20230301950A1/en active Pending
- 2021-06-28 WO PCT/JP2021/024382 patent/WO2021261601A1/ja unknown
- 2021-06-28 EP EP21830069.7A patent/EP4173639A4/en active Pending
- 2021-06-28 JP JP2022532558A patent/JP7327855B2/ja active Active
- 2021-06-28 TW TW110123617A patent/TW202216133A/zh unknown
- 2021-06-28 CA CA3184767A patent/CA3184767A1/en active Pending
- 2021-06-28 CN CN202180045356.5A patent/CN115997122A/zh active Pending
- 2021-06-28 KR KR1020237000437A patent/KR20230031285A/ko unknown
Patent Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
US20040248871A1 (en) | 2001-08-03 | 2004-12-09 | Jean Farjanel | Use of lysyl oxidase inhibitors for cell culture and tissue engineering |
WO2005007828A2 (en) | 2003-07-14 | 2005-01-27 | Prolx Pharmaceuticals, Inc. | Regulation of hif protein levels via deubiquitination pathways |
WO2006026430A2 (en) | 2004-08-27 | 2006-03-09 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogues and methods of use thereof |
WO2006028958A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
WO2007131201A2 (en) | 2006-05-05 | 2007-11-15 | Irm Llc | Compounds and compositions as hedgehog pathway modulators |
WO2008009437A2 (en) | 2006-07-18 | 2008-01-24 | Noxxon Pharma Ag | Sdf-i binding nucleic acids |
JP2017048225A (ja) * | 2007-03-30 | 2017-03-09 | 日東電工株式会社 | がん細胞および癌随伴線維芽細胞への標的化剤 |
US20090005416A1 (en) | 2007-06-29 | 2009-01-01 | Pfizer Inc. | Benzimidazole derivatives |
WO2009017833A2 (en) | 2007-08-02 | 2009-02-05 | Arresto Biosciences | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
US20090053224A1 (en) | 2007-08-02 | 2009-02-26 | Arresto Biosciences | Lox and loxl2 inhibitors and uses thereof |
WO2009019007A2 (en) | 2007-08-06 | 2009-02-12 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof |
WO2009107850A2 (en) | 2008-02-26 | 2009-09-03 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
WO2010147917A1 (en) | 2009-06-19 | 2010-12-23 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
WO2011097513A1 (en) | 2010-02-04 | 2011-08-11 | Gilead Biologics, Inc | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
WO2012012300A2 (en) | 2010-07-20 | 2012-01-26 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
WO2012031773A1 (en) | 2010-09-09 | 2012-03-15 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
WO2012049277A1 (en) | 2010-10-14 | 2012-04-19 | Proximagen Ltd | Cxcr4 receptor antagonists |
WO2013048164A1 (en) | 2011-09-27 | 2013-04-04 | Dongguk University Industry-Academic Cooperation Foundation | NOVEL COMPOUNDS AS HIF-1αINHIBITORS AND MANUFACTURING PROCESS THEREOF |
WO2014001464A1 (en) | 2012-06-27 | 2014-01-03 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
WO2015035223A1 (en) | 2013-09-09 | 2015-03-12 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
WO2015178426A1 (ja) * | 2014-05-21 | 2015-11-26 | 国立研究開発法人産業技術総合研究所 | がん幹細胞の増殖抑制剤 |
WO2016144703A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
WO2016157149A1 (en) | 2015-04-02 | 2016-10-06 | Proximagen Limited | Novel therapies for cancer |
WO2017136871A1 (en) | 2016-02-12 | 2017-08-17 | Pharmaxis Ltd. | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof |
WO2017136870A1 (en) | 2016-02-12 | 2017-08-17 | Pharmaxis Ltd. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
WO2018011376A1 (en) | 2016-07-13 | 2018-01-18 | Centre National De La Recherche Scientifique - Cnrs - | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines |
US20180201640A1 (en) | 2017-01-13 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | 4-methylumbelliferone derivatives for treatment for immune modulation |
WO2018157190A1 (en) | 2017-03-02 | 2018-09-07 | Pharmaxis Ltd. | Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof |
WO2020024017A1 (en) | 2018-08-03 | 2020-02-06 | Pharmaxis Ltd. | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof |
WO2021012014A1 (en) | 2019-07-25 | 2021-01-28 | Pharmaxis Ltd. | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof |
Non-Patent Citations (17)
Title |
---|
"Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis", CANCER RES, vol. 79, 2019, pages 5367 - 81 |
BIOCHEM PHARMACOL, vol. 66, no. 4, 15 August 2003 (2003-08-15), pages 633 - 41 |
CANCER CELL, vol. 25, 2014, pages 719 - 734 |
CANCER CELL, vol. 25, 2014, pages 735 - 747 |
CAS, no. 2007885-39-2 |
CELL, vol. 159, no. 1, 25 September 2014 (2014-09-25), pages 80 - 93 |
DR. DAVID TUVESON: "Cell", vol. 160, 15 January 2015, COLD SPRING HARBOR LABORATORY, article "Organoid models of human and mouse ductal pancreatic cancer", pages: 324 - 38 |
ENOMOTO, ATSUSHI: "Significance of the mechanobiology of cancer stroma in understanding cancer", EXPERIMENTAL MEDICINE, vol. 38, no. 7, 1 May 2020 (2020-05-01), JP , pages 1160 (100) - 1166 (106), XP009542134, ISSN: 0288-5514 * |
GASTROENTEROLOGY, vol. 141, no. 4, October 2011 (2011-10-01), pages 1486 - 97 |
GUT, vol. 55, no. 1, January 2006 (2006-01-01), pages 79 - 89 |
HINGORANI ET AL.: "Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice", CANCER CELL, vol. 7, 2005, pages 469 - 483, XP002610640 |
MAEDA K ET AL., SCI REP, vol. 6, 29 February 2016 (2016-02-29), pages 22288 |
MAEDA K ET AL.: "Identification of Meflin as a potential marker for mesenchymal stromal cells", SCI REP, vol. 6, 2016, pages 22288, XP055845925, DOI: 10.1038/srep22288 |
MIYAI YUKI, ESAKI NOBUTOSHI, TAKAHASHI MASAHIDE, ENOMOTO ATSUSHI: "Cancer‐associated fibroblasts that restrain cancer progression: Hypotheses and perspectives", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 111, no. 4, 1 April 2020 (2020-04-01), JP , pages 1047 - 1057, XP055893621, ISSN: 1347-9032, DOI: 10.1111/cas.14346 * |
MIZUTANI YASUYUKI, KOBAYASHI HIROKI, IIDA TADASHI, ASAI NAOYA, MASAMUNE ATSUSHI, HARA AKITOSHI, ESAKI NOBUTOSHI, USHIDA KAORI, MII: "Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 79, no. 20, 15 October 2019 (2019-10-15), US , pages 5367 - 5381, XP055845782, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-19-0454 * |
NAT COMMUN, vol. 7, 7 September 2016 (2016-09-07), pages 12630 |
See also references of EP4173639A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023210634A1 (ja) * | 2022-04-28 | 2023-11-02 | 国立大学法人東海国立大学機構 | 拡張障害を伴う心不全の治療用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP7327855B2 (ja) | 2023-08-16 |
CA3184767A1 (en) | 2021-12-30 |
EP4173639A4 (en) | 2024-03-13 |
JPWO2021261601A1 (ja) | 2021-12-30 |
CN115997122A (zh) | 2023-04-21 |
KR20230031285A (ko) | 2023-03-07 |
TW202216133A (zh) | 2022-05-01 |
EP4173639A1 (en) | 2023-05-03 |
US20230301950A1 (en) | 2023-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6132833B2 (ja) | 抗癌療法としての正常細胞および腫瘍細胞の小分子trail遺伝子誘導 | |
US11338014B2 (en) | Methods and compositions for treatment of endothelin B receptor expressing tumors | |
US10160972B2 (en) | Methods and materials for treating cancer | |
JP2014514326A5 (ja) | ||
KR101877840B1 (ko) | 암 치료용 화합물을 확인하는 방법 | |
EA023864B1 (ru) | Применение мацитентана в комбинации с цитотоксическим химиотерапевтическим средством и/или лучевой терапией для лечения метастазов в головном мозге | |
WO2021239817A1 (en) | Therapeutic combinations comprising agonists of ferroptosis for treating proliferative disorders | |
US20200289495A1 (en) | Methods of inhibiting endothelin b receptor expressing tumor metastases | |
WO2021261601A1 (ja) | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 | |
US20200308585A1 (en) | Targeting glioblastoma stem cells through the tlx-tet3 axis | |
US20200268829A1 (en) | Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer | |
CN115381949A (zh) | 靶向抑制色素上皮衍生因子在促进肝脏再生及改善肝损伤中的应用 | |
CN109303783B (zh) | 自噬抑制剂在制备增强石蒜碱抗肝癌活性药物中的应用 | |
CN112007164B (zh) | 降低tcrp1的表达或活性的试剂在制备增强石蒜碱的抗肝癌活性药物中的应用 | |
CN109303919B (zh) | Akt抑制剂在制备增强石蒜碱的抗肝癌活性药物中的应用 | |
US20200282009A1 (en) | Methods of treating diseases associated with vascular smooth muscle cell proliferation | |
WO2023278603A2 (en) | Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1), combinations and uses thereof | |
JP2023098645A (ja) | 治療抵抗性がん細胞制御剤及び抗がん剤の抗腫瘍作用増強剤 | |
WO2002084284A2 (en) | Diagnosis and treatment of cancer:ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21830069 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022532558 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3184767 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021830069 Country of ref document: EP Effective date: 20230126 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |